


09171671 09/171671
300 Rec'd PCT/PTO 23 OCT 1998

FORM PTO-1390 (REV. 5/93)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket Number 179-28
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known, see 37 C.F.R. 1.5) (To Be Assigned)	
International Application No. PCT/GB97/01158 ✓	International Filing Date 24 April 1997 ✓	Priority Date Claimed 24 April 1996 ✓	
Title of Invention AUTO-DECONVOLUTING COMBINATORIAL LIBRARIES ✓			
Applicant(s) For DO/EO/US QUIBELL et al			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. The above checked items are being transmitted: a. <input type="checkbox"/> before the 18 th month publication. b. <input type="checkbox"/> after publication and the Article 20 communication but before 20 months from the priority date. c. <input type="checkbox"/> after 20 months. d. <input checked="" type="checkbox"/> by 30 months and a proper demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. e. <input type="checkbox"/> after 30 months. Note: Petition to revive (37 CFR 1.137(a) or (b)) is necessary if 35 U.S.C. 371 requirements submitted (1) after 20 months and no proper demand for International Preliminary Examination was made by 19 months from the earliest claimed priority date, or (2) after 30 months and a proper demand for International Preliminary Examination was made by 19 months from the earliest claimed priority date. 12. At the time of transmittal, Amendments to the claims under Article 34 a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 13. <input type="checkbox"/> Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on _____, namely: 14. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 15. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 16. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND OR SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter.			

Attorney's Docket Number 179-28

19. <input checked="" type="checkbox"/> Other items or information: International Search Report; Sequence Listing						CALCULATION		PT USE ONLY	
20. <input checked="" type="checkbox"/> The following fees are submitted:						S			
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)) -- Search Report has been prepared by the EPO or JPO\$930.00 -- International preliminary examination fee paid to USPTO (37 CFR 1.492).....\$720.00 -- No international preliminary examination fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$790.00 -- Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,070.00 -- International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provision of PCT Article 33(1) to (4).....\$98.00									
ENTER APPROPRIATE BASIC FEE AMOUNT =						\$	930.00		
Surcharge of \$130.00 for furnishing the National fee or oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)).						\$	130.00		
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE					
Total Claims		14	-20 = 0	X	\$22.00	\$	0.00		
Independent Claims		1	-3 = 0	X	\$82.00	\$	0.00		
Multiple Dependent Claims(s) (if applicable)							+\$270.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =						\$	1060.00		
Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed also. (Note 37 CFR 1.9, 1.27, 1.28).							0.00		
SUBTOTAL =						\$	1060.00		
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos., from the earliest claimed priority date (37 CFR 1.492(f)).							0.00		
TOTAL NATIONAL FEE =						\$	1060.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						\$	0.00		
Fee for Petition to Revive Unintentionally Abandoned Application (\$1,320 - Small Entity Fee = \$660)						\$	0.00		
TOTAL FEES ENCLOSED =						\$	1060.00		
						Amount to be refunded		\$	
						Charged		\$	
a. A check in the amount of \$1060.00 to cover the above fees is enclosed. <input checked="" type="checkbox"/> b. Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. <input type="checkbox"/> c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>14-1140</u> . A duplicate copy of this form is enclosed. <input checked="" type="checkbox"/>						Signature  Leonard C. Mitchard Name			
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201 Telephone: (703) 816-4000						29,009 Registration Number		October 23, 1998 Date	

Rec'd PCT/PTO 18 OCT 2002
10/171671

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

QUIBELL et al

Atty. Ref.: 179-28

Serial No. 09/171,671

Group:

Filed: October 23, 1998

Examiner:

For: AUTO-DECONVOLUTING COMBINATORIAL LIBRARIES

* * * * *

October 22, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

Please amend the above application as follows:

IN THE SPECIFICATION:

Please substitute the following paragraphs in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Page 55, beginning at line 16:

[SEQ ID NO: 1]	Abz-Val-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	12
[SEQ ID NO: 2]	H-Val-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS

09/171671

300 Rec'd PCT/PTO 23 OCT 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

QUIBELL et al

Atty. Ref.: 179-28

Serial No. (To Be Assigned)

Group:

Filed: **October 23, 1998**

Examiner:

For: **AUTO-DECONVOLUTING
COMBINATORIAL LIBRARIES**

* * * * *

October 23, 1998

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for
examination, please amend the application as follows:

IN THE CLAIMS

Claim 14, line 1, delete, "or 3".

QUIBELL et al
Serial No. (To Be Assigned)


REMARKS

The above amendments are made to place the claims in a more traditional
format.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:pd
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

[SEQ ID NO: 3]	H-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 4]	Ac -Val-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 5]	H-Val-Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NS
[SEQ ID NO: 6]	H-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 7]	Ac-Val -Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NS
[SEQ ID NO: 8]	Abz-Val-Ala-Nle-Ser-Tyr (NO ₂) NH ₂	NM
[SEQ ID NO: 9]	Abz -Val -Ala-Nle-Ser-NH ₂	NM

Page 56, beginning at line 1:

[SEQ ID NO: 10]	Abz-Val-Ala-Nle-Ser-Phe-Asp-NH ₂	NM
[SEQ ID NO: 11]	Abz-Val -Ala-Nle-Ser-Tyr-Asp-NH ₂	NM
[SEQ ID NO: 12]	Abz-Val -Ala-Nle-Ser-Ala-Asp-NH ₂	NM
[SEQ ID NO: 13]	Abz-Val -Ala-Nle-Ser-Lys -Asp-NH ₂	NM
[SEQ ID NO: 14]	Abz -Val -Ala-Nle-Ser-eAHA-Asp-NH ₂	NM
[SEQ ID NO: 15]	Abz-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 16]	Abz-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 17]	Bz-Val-Ala-Nle-Ser-Tyr (NO ₂) NH ₂	NM ^a
[SEQ ID NO: 18]	Bz(2-carboxy) -Val-Ala-Nle-Ser-Tyr (NO ₂)-NH ₂	NM ^a
[SEQ ID NO: 19]	Chex-Val-Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NM ^a
[SEQ ID NO: 20]	n-Bu-Val-Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NM ^a
[SEQ ID NO: 21]	Piv-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
[SEQ ID NO: 22]	Bz-Val-Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NM ^a

[SEQ ID NO: 23]	Abz-Val-Ala-Lys-Ser-Tyr (NO ₂) -Asp-NH ₂	14
[SEQ ID NO: 24]	Abz-Val-Ala-Gln-Ser-Tyr (NO ₂) -Asp-NH ₂	6
[SEQ ID NO: 25]	Abz-Val-Ala-Thr-Ser-Tyr (NO ₂) -Asp-NH ₂	6
[SEQ ID NO: 26]	Abz-Val-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	4
[SEQ ID NO: 27]	Abz-Val-Ala-Cha-Ser-Tyr (NO ₂) -Asp-NH ₂	5
[SEQ ID NO: 28]	Abz-Val-Ala-His-Ser-Tyr (NO ₂) -Asp-NH ₂	20
[SEQ ID NO: 29]	Abz-Val-Ala-ACH-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 30]	Abz-Val-Ala-DNle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 31]	Abz-Val-Ala-3pyr-Ser-Tyr (NO ₂) -Asp-NH ₂	10
[SEQ ID NO: 32]	Abz-Val-Ala-Hyp-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 33]	Abz-Val-Ala-ACP-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 34]	Abz-VTal-Lys-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	35
[SEQ ID NO: 35]	Abz-Val-DAla-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS

Page 57, beginning at line 1:

[SEQ ID NO: 36]	Abz-Val-Tic-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 37]	Abz-Val-ACH-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 38]	Abz-Val-Met (O) -hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	35
[SEQ ID NO: 39]	Abz-Val-2Nal-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 40]	Abz-Val-ACP-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 41]	Abz-Val-DLys-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 42]	Abz-Val-DGln-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS

[SEQ ID NO: 43]	Abz-Val-3pyr-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 44]	Abz-Val-Cha-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 45]	Abz-DVal-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 46]	Abz-Gln-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	12
[SEQ ID NO: 47]	Abz-Lys-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	15
[SEQ ID NO: 48]	Abz-Tic-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 49]	Abz-ACH-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 50]	Abz-Met(O)-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	20
[SEQ ID NO: 51]	Abz-3pyr-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	10
[SEQ ID NO: 52]	Abz-2Nal-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	15
[SEQ ID NO: 53]	Abz-Leu-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	18
[SEQ ID NO: 54]	Abz-Cha-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	9
[SEQ ID NO: 55]	Abz-Bip-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	2.5
[SEQ ID NO: 56]	Abz-Bip-Ala-hLeu-Tyr-Tyr(NO ₂)-Asp-NH ₂	3
[SEQ ID NO: 57]	Abz-Bip-Ala-hLeu-Leu-Tyr(NO ₂)-Asp-NH ₂	3.7
[SEQ ID NO: 58]	Abz-Bip-Ala-hLeu-Lys-Tyr(NO ₂)-Asp-NH ₂	2
[SEQ ID NO: 59]	Abz-Bip-Ala-hLeu-Asp-Tyr(NO ₂)-Asp-NH ₂	5.0
[SEQ ID NO: 60]	Abz-Bip-Ala-hLeu-Abu-Tyr(NO ₂)-Asp-NH ₂	1.7
[SEQ ID NO: 61]	Abz-Bip-Ala-hLeu-Cha-Tyr(NO ₂)-Asp-NH ₂	2.5
[SEQ ID NO: 62]	Abz-Bip-Ala-hLeu-Met(O)-Tyr(NO ₂)-Asp-NH ₂	5

Page 58, beginning at line 1:

[SEQ ID NO: 63]	Abz-Bip-Ala-hLeu-Thr-Tyr (NO ₂)-Asp-NH ₂	2.5
[SEQ ID NO: 64]	Abz-Bip-Ala-hLeu-3pyr-Tyr (NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 65]	Abz-Bip-Ala-hLeu-Bu ^t Gly-Tyr(NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 66]	Abz-Bip-Ala-hLeu-Hyp-Tyr (NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 67]	Abz-Phe-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 68]	Abz-3-Pyr-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 69]	Abz-1.Naph-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	17
[SEQ ID NO: 70]	Abz-2.Naph-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 71]	Abz-Tyr-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 72]	Abz-Bip-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	10
[SEQ ID NO: 73]	Abz-Lys-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	15
[SEQ ID NO: 74]	Abz-Glu-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	20
[SEQ ID NO: 75]	Abz-Leu-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 76]	Abz-Hyp-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

Page 59, beginning at line 23:

[SEQ ID NO: 77]	Abz-Val-Ala- (NMe)Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 78]	Abz-Val-_(NMe)Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

Page 60, beginning at line 1:

[SEQ ID NO: 79]	Abz-Val-Ala-Aib-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 80]	Abz-Val-Aib-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 81]	Abz-Deg-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

[SEQ ID NO: 82]	nBu-D.Ser-D.Nle-D.Ala-D.Val-p.Aba-NH ₂	NS
[SEQ ID NO: 83]	Bz-Val-Ala-Statine-Ser-eAha-NH ₂	NS
[SEQ ID NO: 84]	Abz-p .Aba-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 85]	Abz-Cmpi-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

REMARKS


The specification has been amended to insert the individual SEQ ID numbers corresponding to the sequence listing materials submitted herewith. No new matter is entered.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Page 55, beginning at line 16:

[SEQ ID NO: 1]	Abz-Val-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	12
[SEQ ID NO: 2]	H-Val-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 3]	H-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 4]	Ac -Val-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 5]	H-Val-Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NS
[SEQ ID NO: 6]	H-Ala-Nle-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 7]	Ac-Val -Ala-Nle-Ser-Tyr (NO ₂) -NH ₂	NS
[SEQ ID NO: 8]	Abz-Val-Ala-Nle-Ser-Tyr (NO ₂) NH ₂	NM
[SEQ ID NO: 9]	Abz -Val -Ala-Nle-Ser-NH ₂	NM

Page 56, beginning at line 1:

[SEQ ID NO: 10]	Abz-Val-Ala-Nle-Ser-Phe-Asp-NH ₂	NM
[SEQ ID NO: 11]	Abz-Val -Ala-Nle-Ser-Tyr-Asp-NH ₂	NM
[SEQ ID NO: 12]	Abz-Val -Ala-Nle-Ser-Ala-Asp-NH ₂	NM
[SEQ ID NO: 13]	Abz-Val -Ala-Nle-Ser-Lys -Asp-NH ₂	NM
[SEQ ID NO: 14]	Abz -Val -Ala-Nle-Ser-eAHA-Asp-NH ₂	NM
[SEQ ID NO: 15]	Abz-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 16]	Abz-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 17]	Bz-Val-Ala-Nle-Ser-Tyr (NO ₂) NH ₂	NM ^a

[SEQ ID NO: 18]	Bz(2-carboxy)-Val-Ala-Nle-Ser-Tyr (NO ₂)-NH ₂	NM ^a
[SEQ ID NO: 19]	Chex-Val-Ala-Nle-Ser-Tyr (NO ₂)-NH ₂	NM ^a
[SEQ ID NO: 20]	n-Bu-Val-Ala-Nle-Ser-Tyr (NO ₂)-NH ₂	NM ^a
[SEQ ID NO: 21]	Piv-Val-Ala-Nle-Ser-Tyr(NO ₂)-NH ₂	NM ^a
[SEQ ID NO: 22]	Bz-Val-Ala-Nle-Ser-Tyr (NO ₂)-NH ₂	NM ^a
[SEQ ID NO: 23]	Abz-Val-Ala-Lys-Ser-Tyr (NO ₂)-Asp-NH ₂	14
[SEQ ID NO: 24]	Abz-Val-Ala-Gln-Ser-Tyr (NO ₂)-Asp-NH ₂	6
[SEQ ID NO: 25]	Abz-Val-Ala-Thr-Ser-Tyr (NO ₂)-Asp-NH ₂	6
[SEQ ID NO: 26]	Abz-Val-Ala-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 27]	Abz-Val-Ala-Cha-Ser-Tyr (NO ₂)-Asp-NH ₂	5
[SEQ ID NO: 28]	Abz-Val-Ala-His-Ser-Tyr (NO ₂)-Asp-NH ₂	20
[SEQ ID NO: 29]	Abz-Val-Ala-ACH-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 30]	Abz-Val-Ala-DNle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 31]	Abz-Val-Ala-3pyr-Ser-Tyr (NO ₂)-Asp-NH ₂	10
[SEQ ID NO: 32]	Abz-Val-Ala-Hyp-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 33]	Abz-Val-Ala-ACP-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 34]	Abz-VTal-Lys-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	35
[SEQ ID NO: 35]	Abz-Val-DAla-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

Page 57, beginning at line 1:

[SEQ ID NO: 36]	Abz-Val-Tic-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 37]	Abz-Val-ACH-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

[SEQ ID NO: 38]	Abz-Val-Met (O) -hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	35
[SEQ ID NO: 39]	Abz-Val-2Nal-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 40]	Abz-Val-ACP-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 41]	Abz-Val-DLys-hLeu-Ser-Tyr (NO ₂)-Asp-NH ₂	NS
[SEQ ID NO: 42]	Abz-Val-DGln-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 43]	Abz-Val-3pyr-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 44]	Abz-Val-Cha-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 45]	Abz-DVal-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 46]	Abz-Gln-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	12
[SEQ ID NO: 47]	Abz-Lys-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	15
[SEQ ID NO: 48]	Abz-Tic-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 49]	Abz-ACH-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	NS
[SEQ ID NO: 50]	Abz-Met (O) -Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	20
[SEQ ID NO: 51]	Abz-3pyr-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	10
[SEQ ID NO: 52]	Abz-2Nal-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	15
[SEQ ID NO: 53]	Abz-Leu-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	18
[SEQ ID NO: 54]	Abz-Cha-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	9
[SEQ ID NO: 55]	Abz-Bip-Ala-hLeu-Ser-Tyr (NO ₂) -Asp-NH ₂	2.5
[SEQ ID NO: 56]	Abz-Bip-Ala-hLeu-Tyr-Tyr (NO ₂) -Asp-NH ₂	3
[SEQ ID NO: 57]	Abz-Bip-Ala-hLeu-Leu-Tyr (NO ₂) -Asp-NH ₂	3.7
[SEQ ID NO: 58]	Abz-Bip-Ala-hLeu-Lys-Tyr (NO ₂) -Asp-NH ₂	2
[SEQ ID NO: 59]	Abz-Bip-Ala-hLeu-Asp-Tyr (NO ₂) -Asp-NH ₂	5.0

[SEQ ID NO: 60]	Abz-Bip-Ala-hLeu-Abu-Tyr (NO ₂)-Asp-NH ₂	1.7
[SEQ ID NO: 61]	Abz-Bip-Ala-hLeu-Cha-Tyr (NO ₂)-Asp-NH ₂	2.5
[SEQ ID NO: 62]	Abz-Bip-Ala-hLeu-Met (O)-Tyr (NO ₂)-Asp-NH ₂	5

Page 58, beginning at line 1:

[SEQ ID NO: 63]	Abz-Bip-Ala-hLeu-Thr-Tyr (NO ₂)-Asp-NH ₂	2.5
[SEQ ID NO: 64]	Abz-Bip-Ala-hLeu-3pyr-Tyr (NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 65]	Abz-Bip-Ala-hLeu-Bu ^t Gly-Tyr(NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 66]	Abz-Bip-Ala-hLeu-Hyp-Tyr (NO ₂)-Asp-NH ₂	4
[SEQ ID NO: 67]	Abz-Phe-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 68]	Abz-3-Pyr-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 69]	Abz-1.Naph-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	17
[SEQ ID NO: 70]	Abz-2.Naph-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 71]	Abz-Tyr-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	M
[SEQ ID NO: 72]	Abz-Bip-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	10
[SEQ ID NO: 73]	Abz-Lys-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	5
[SEQ ID NO: 74]	Abz-Glu-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	20
[SEQ ID NO: 75]	Abz-Leu-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NM
[SEQ ID NO: 76]	Abz-Hyp-Val-Ala-Nle-Ser-Tyr (NO ₂)-Asp-NH ₂	NS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 179-28

In re patent application of

QUIBELL, MARTIN et al.

Serial No. 09/171,671

Filed: 1998-10-23

For: AUTO-DECONVOLUTING COMBINATORIAL LIBRARIES

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and


3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/171,671

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Sept. 25, 2001
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

SEQUENCE LISTING

<110> QUIBELL, MARTIN
JOHNSON, TONY
HART, TERANCE

<120> AUTO-DECONVOLUTING COMBINATORIAL LIBRARIES

<130> 179-28

<140> 09/171,671

<141> 1998-10-23

<150> PCT/GB97/01158

<151> 1997-04-24

<150> GB 9608457.9

<151> 1996-04-24

<150> GB 9616115.3

<151> 1996-07-31

<150> GB 9624584.0

<151> 1996-11-27

<160> 85

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (4)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 1

Xaa Val Ala Xaa Ser Tyr Asp

1

5

<210> 2

<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 2
Val Ala Xaa Ser Tyr Asp
1 5

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (2)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 3
Ala Xaa Ser Tyr Asp
1 5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 4
Val Ala Xaa Ser Tyr Asp
1 5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 5
Val Ala Xaa Ser Tyr
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (2)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 6
Ala Xaa Ser Tyr Asp
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 7
Val Ala Xaa Ser Tyr
1 5

<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 8
Xaa Val Ala Xaa Ser Tyr
1 5

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES

<222> (4)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 9
Xaa Val Ala Xaa Ser
1 5

<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 10
Xaa Val Ala Xaa Ser Phe Asp
1 5

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 11

Xaa Val Ala Xaa Ser Tyr Asp

1

5

<210> 12

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (4)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 12

Xaa Val Ala Xaa Ser Ala Asp

1

5

<210> 13

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (4)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 13
Xaa Val Ala Xaa Ser Lys Asp
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Nle

<220>
<221> MOD_RES
<222> (6)
<223> eAHA

<220>
<223> C-TERM AMIDATION

<400> 14
Xaa Val Ala Xaa Ser Xaa Asp
1 5

<210> 15
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 15
Xaa Ala Xaa Ser Tyr Asp
1 5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 16
Xaa Xaa Ser Tyr Asp
1 5

<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 17
Val Ala Xaa Ser Tyr
1 5

<210> 18
<211> 5

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 18
Val Ala Xaa Ser Tyr
1 5

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)
<223> Chex

<220>
<221> MOD_RES
<222> (4)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 19
Xaa Val Ala Xaa Ser Tyr
1 5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES

<222> (3)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 20

Val Ala Xaa Ser Tyr

1

5

<210> 21

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (1)

<223> Piv

<220>

<221> MOD_RES

<222> (4)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 21

Xaa Val Ala Xaa Ser Tyr

1

5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (3)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 22

Val Ala Xaa Ser Tyr

1

5

<210> 23
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<223> C-TERM AMIDATION

<400> 23
Xaa Val Ala Lys Ser Tyr Asp
1 5

<210> 24
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<223> C-TERM AMIDATION

<400> 24
Xaa Val Ala Gln Ser Tyr Asp
1 5

<210> 25
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES

12

<222> (1)
<223> Abz

<220>
<223> C-TERM AMIDATION

<400> 25
Xaa Val Ala Thr Ser Tyr Asp
1 5

<210> 26
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 26
Xaa Val Ala Leu Ser Tyr Asp
1 5

<210> 27
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Cha

<220>

<223> C-TERM AMIDATION

<400> 27

Xaa Val Ala Xaa Ser Tyr Asp

1

5

<210> 28

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<223> C-TERM AMIDATION

<400> 28

Xaa Val Ala His Ser Tyr Asp

1

5

<210> 29

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (4)

<223> ACH

<220>

<223> C-TERM AMIDATION

<400> 29

Xaa Val Ala Xaa Ser Tyr Asp

1

5

<210> 30
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> DNle

<220>
<223> C-TERM AMIDATION

<400> 30
Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 31
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> 3pyr

<220>
<223> C-TERM AMIDATION

<400> 31
Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 32
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Hyp

<220>
<223> C-TERM AMIDATION

<400> 32
Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 33
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> ACP

<220>
<223> C-TERM AMIDATION

<400> 33
Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 34
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 34
Xaa Val Lys Leu Ser Tyr Asp
1 5

<210> 35
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> DAla

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 35
Xaa Val Ala Leu Ser Tyr Asp
1 5

<210> 36
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> Tic

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 36
Xaa Val Xaa Leu Ser Tyr Asp
1 5

<210> 37
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> ACH

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 37
Xaa Val Xaa Leu Ser Tyr Asp
1 5

<210> 38
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> Met (O)

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 38
Xaa Val Met Leu Ser Tyr Asp
1 5

<210> 39
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> 2Nal

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>

<223> C-TERM AMIDATION

<400> 39

Xaa Val Xaa Leu Ser Tyr Asp

1

5

<210> 40

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (3)

<223> ACP

<220>

<221> MOD_RES

<222> (4)

<223> hLeu

<220>

<223> C-TERM AMIDATION

<400> 40

Xaa Val Xaa Leu Ser Tyr Asp

1

5

<210> 41

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (3)

<223> DLys

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 41
Xaa Val Lys Leu Ser Tyr Asp
1 5

<210> 42
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> DGLn

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 42
Xaa Val Gln Leu Ser Tyr Asp
1 5

<210> 43
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES

<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> 3pyr

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 43
Xaa Val Xaa Leu Ser Tyr Asp
1 5

<210> 44
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> Cha

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 44
Xaa Val Xaa Leu Ser Tyr Asp
1 5

<210> 45
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> DVal

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 45
Xaa Val Ala Leu Ser Tyr Asp
1 5

<210> 46
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 46
Xaa Gln Ala Leu Ser Tyr Asp
1 5

<210> 47
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 47
Xaa Lys Ala Leu Ser Tyr Asp
1 5

<210> 48
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Tic

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 48
Xaa Xaa Ala Leu Ser Tyr Asp
1 5

<210> 49
<211> 7

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> ACH

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 49
Xaa Xaa Ala Leu Ser Tyr Asp
1 5

<210> 50
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Met (O)

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 50

Xaa Met Ala Leu Ser Tyr Asp

1

5

<210> 51

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (2)

<223> 3pyr

<220>

<221> MOD_RES

<222> (4)

<223> hLeu

<220>

<223> C-TERM AMIDATION

<400> 51

Xaa Xaa Ala Leu Ser Tyr Asp

1

5

<210> 52

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (2)

<223> 2Nal

<220>

<221> MOD_RES

<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 52
Xaa Xaa Ala Leu Ser Tyr Asp
1 5

<210> 53
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 53
Xaa Leu Ala Leu Ser Tyr Asp
1 5

<210> 54
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Cha

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 54
Xaa Xaa Ala Leu Ser Tyr Asp
1 5

<210> 55
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 55
Xaa Xaa Ala Leu Ser Tyr Asp
1 5

<210> 56
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 56
Xaa Xaa Ala Leu Tyr Tyr Asp
1 5

<210> 57
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 57
Xaa Xaa Ala Leu Leu Tyr Asp
1 5

<210> 58
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 58
Xaa Xaa Ala Leu Lys Tyr Asp
1 5

<210> 59
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 59
Xaa Xaa Ala Leu Asp Tyr Asp
1 5

<210> 60
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<221> MOD_RES
<222> (5)
<223> Abu

<220>
<223> C-TERM AMIDATION

<400> 60
Xaa Xaa Ala Leu Xaa Tyr Asp
1 5

<210> 61
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

```
<210> 63
<211> 7
```


<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<223> C-TERM AMIDATION

<400> 63
Xaa Xaa Ala Leu Thr Tyr Asp
1 5

<210> 64
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (4)
<223> hLeu

<220>
<221> MOD_RES
<222> (5)
<223> 3pyr

<220>

<223> C-TERM AMIDATION

<400> 64

Xaa Xaa Ala Leu Xaa Tyr Asp

1

5

<210> 65

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> Abz

<220>

<221> MOD_RES

<222> (2)

<223> Bip

<220>

<221> MOD_RES

<222> (4)

<223> hLeu

<220>

<221> MOD_RES

<222> (5)

<223> BuGly

<220>

<223> C-TERM AMIDATION

<400> 65

Xaa Xaa Ala Leu Gly Tyr Asp

1

5

<210> 66

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> 3pyr

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 68
Xaa Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 69
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Naph

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 69
Xaa Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 70
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Naph

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 70
Xaa Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 71
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 71
Xaa Tyr Val Ala Xaa Ser Tyr Asp
1 5

<210> 72
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Bip

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 72
Xaa Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 73
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 73
Xaa Lys Val Ala Xaa Ser Tyr Asp
1 5

<210> 74
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 74
Xaa Glu Val Ala Xaa Ser Tyr Asp
1 5

<210> 75
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 75
Xaa Leu Val Ala Xaa Ser Tyr Asp
1 5

<210> 76
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Hyp

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 76
Xaa Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 77
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> (NMe)Nle

<220>
<223> C-TERM AMIDATION

<400> 77
Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 78
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (3)
<223> (NMe)Ala

<220>
<221> MOD_RES
<222> (4)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 78
Xaa Val Ala Xaa Ser Tyr Asp
1 5

<210> 79
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (4)
<223> Aib

<220>
<223> C-TERM AMIDATION

<222> (4)

<223> Nle

<220>

<223> C-TERM AMIDATION

<400> 81

Xaa Xaa Ala Xaa Ser Tyr Asp

1

5

<210> 82

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (1)

<223> DSer

<220>

<221> MOD_RES

<222> (2)

<223> DNle

<220>

<221> MOD_RES

<222> (3)

<223> DAla

<220>

<221> MOD_RES

<222> (4)

<223> DVal

<220>

<221> MOD_RES

<222> (5)

<223> p.Aba

<220>

<223> C-TERM AMIDATION

<400> 82

Ser Xaa Ala Val Xaa

1

5

<210> 83

<211> 5

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Statine

<220>
<221> MOD_RES
<222> (5)
<223> eAha

<220>
<223> C-TERM AMIDATION

<400> 83
Val Ala Xaa Ser Xaa
1 5

<210> 84
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> p.Aba

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 84
Xaa Xaa Xaa Ser Tyr Asp
1 5

<210> 85
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> Abz

<220>
<221> MOD_RES
<222> (2)
<223> Cmpi

<220>
<221> MOD_RES
<222> (3)
<223> Nle

<220>
<223> C-TERM AMIDATION

<400> 85
Xaa Xaa Xaa Ser Tyr Asp
1 5

17PRTS

WO 97/42216

09171671

09/171671

PCT/GB97/01158

300 Rec'd PCT/PTO 23 OCT 1998

- 1 -

Auto-Deconvoluting Combinatorial Libraries

The present invention relates to the field of apparatus and methods which provide the rapid generation of structure/activity relationships using auto-deconvoluting combinatorial libraries, which facilitate the invention of novel active compounds. The invention provides apparatus and methods which can be used for the rapid generation of structure/activity relationship (SAR) data, and, therefore, the characterisation of the active motif of any group of compounds.

The invention provides libraries of compounds which interact with an active moiety, and apparatus and methods to identify such compounds. The active moieties may be (but are not limited to) enzymes, receptors, antibodies, etc. The interaction of the active moiety with the compounds of the library may be (but is not limited to) the interaction of a substrate or inhibitor with an enzyme, the interaction of a ligand with a receptor, the interaction of an antigen or antigenic epitope with an antibody, etc.

The following list illustrates a number of enzyme classes and subclasses:

Enzyme Classes

1. Oxidoreductase
 - a) dehydrogenase
 - b) oxidase
 - c) peroxidase

- 2 -

- d) catalase
- 2. Hydrolase
 - f) peptidase (proteolytic enzyme)
- 3. Transferase
 - 5 g) aminotransferase
 - h) kinase
 - i) glucosyltransferase
- 4. Lyase
 - j) decarboxylase
 - 10 k) dehydratease
- 5. Isomerase
 - l) racemase
 - m) mutase
- 6. Ligase
 - 15 n) synthetase
 - o) carboxylase

Proteases of interest include (but are not limited to):

- 1. Aspartyl proteases, such as renin, HIV, cathepsin D and cathepsin E etc.
- 20 2. Metalloproteases, such as ECE, gelatinase A and B, collagenases, stromolysins etc.
- 3. Cysteinyll proteases, such as apopain, ICI, DerPI, cathepsin B, cathepsin K etc.

- 3 -

4. Serine proteases, such as thrombin, factor VIIa, factor Xa, elastase, trypsin.

5. Threonyl proteases, such as proteasome S.

Proteases

5 Many therapeutically useful drugs act as enzyme inhibitors. In particular, proteolytic enzyme inhibitors have been the focus of much attention in the pharmaceutical industry, because they play a variety of roles in a multitude of biological systems. Their
10 proteolytic activities are related to processes ranging from cell invasion associated with metastatic cancer to evasion of an immune response, as seen in certain parasitic organisms; from nutrition to intracellular signalling to the site-specific proteolysis of viral
15 proteases and eukaryotic hormone-processing enzymes. However, the traditional random screening methods for the identification of lead molecules as inhibitors of proteolytic enzymes are often laborious and time-consuming. Therefore new and efficient methods which can
20 accelerate the drug discovery process are greatly in demand.

We consider that proteases contain an active catalytic site which tends to become increasingly activated as the recognition pockets¹ (S₁ and S₂ etc) and (S₁' and S₂' etc)
25 become better occupied. Therefore, it is important that those parts (P₁ and P₂ etc) (P₁' and P₂' etc) of the inhibitor that best fit into these pockets are identified as quickly as possible in order to design novel protease

- 4 -

inhibitors. Therefore, we have devised a combinatorial method for the rapid identification of these binding motifs which will greatly expedite the synthesis of inhibitors of a variety of proteolytic enzymes such as aspartyl proteases, serine proteases, metallo proteases and cysteinyl proteases.

The use of a fluorescence resonance energy transfer (FRET) substrate for the analysis of proteolytic enzyme specificity was first published by Carmel.² Since then many different quenched fluorogenic substrates for measuring enzyme inhibition have been described in the literature.⁴⁻¹¹ These substrates contain a fluorophore, F, in a P position (*vide supra*), which is quenched by another group, Q, present in a P' position (*vide supra*) and separated from F by the scissile bond. The advantage of the positioning of these residues, F and Q, is that cleavage of a peptide bond occurs between the two natural residues and, therefore, represents a more natural hydrolytic event rather than the cleavage and release of a C-terminal chromophore.

For example, Bratovanova and Petkov¹² have synthesised fluorogenic substrates from peptide 4-nitroanilides. N-acylation of peptide 4-nitroanilides with the aminobenzoyl (ABz) group yielded substrates that are internally quenched by the presence of the 4-nitroanilide moiety. Upon hydrolysis of the aminoacyl-4-nitroanilide bond, the highly fluorescent N-ABz group is released attached either to an amino acid or peptide.

- 5 -

Immobilised libraries, where substrates are attached to a polymer or biopolymer support, have also been used for mapping protease binding sites.¹³ Singh et al. reported recently that enzymatic substrate activity of 38 selected octapeptides attached via a linker to controlled pore glass is predictive of the same activity of similar peptides in solution. However, these results are preliminary and only for a specific example. Therefore, it is not clear whether immobilised substrates attached to polymers can reliably replace soluble substrates in mapping the hindered protease binding sites, especially since the hydrophilic or lipophilic nature of the polymer and the size of the interstices within the polymer are bound to influence the reaction between the enzyme and its substrates.

Mixtures of internally quenched, fluorogenic substrates have also recently been described in which the quencher group, Q, is 2,4-dinitrophenyl (Dnp) and is attached to the P side of the scissile bond, while the fluorogenic group, is N-methyl anthranilic acid (Nma) and is attached to the P' side.¹⁴

Examples of other Donor-Acceptor Chromophore Pairs that have been applied to Biological Systems are shown in Table 1.

Table 1 : Donor-Acceptor Chromophore Pairs That Have Been Applied To Biological Samples

Donor	Acceptor	Donor	Acceptor
Naphthalene	Dansyl	IAEDANS	TNP-ATP
IANBD	DDPM	ϵ -A	IANBD
IAEDANS	DDPM	NBD	SRH

- 6 -

	DNSM	LY	ISA	TNP
	IAEDANS	IANBD	Dansyl	ODR
	E-A	F ₂ DNB	DANZ	IAF
	Pyrene	Bimane	FNAI	EITC
5	ANAI	IPM	NBD	LRH
	IAANS	IAF	IAF	EIA
	ε-A	F ₂ DPS	FITC	ENAI
	ε-A	DDPM	Proflavin	ETSC
	IAEDANS	TNP	CPM	TNP-ATP
10	MNA	DACM	IAEDANS	IAF
	PM	NBD	CPM	Fluorescein
	FITC	TNP-ATP	IAEDANS	FITC
	DANZ	DABM	FITC	TMR
	NCP	CPM	IAF	TMR
15	NAA	DNP	CF	TR
	LY	TNP-ATP	CPM	FTS
	IAF	diI-C ₁₈	ε-A	TNP-ATP
	IAF	TMR	CPM	FM
	FMA	FMA	LY	EM
20	PM	DMAMS	FITC	EITC
	mBBR	FITC	IAEDANS	DiO-C ₁₄
	mBBR	DABM	IAF	ErITC
	ε-A	NBD	FITC	EM
	Pyrene	Coumarin	FITC	ETSC
25	IPM	FNAI	FITC	ErITC
	IAEDANS	DABM	BPE	CY5

- ANAI, 2-anthracene N-acetylimidazole; BPE, B-phycoerythrin; CF, carboxyfluorescein succinimidyl ester; CPM, 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin; CY5, carboxymethylindocyanine-N-hydroxysuccinimidyl ester; diI-C₁₈, 1,1'-dioctadecyl-3,3,3'-tetramethyl-indocarbocyanine; DiO-C₁₄, 3,3'-ditetradecyloxacarbocyanine; DABM, 4-dimethylaniniphenylazo-phenyl-4'-maleimide; DACM, (7-(dimethylamino)coumarin-4-yl)-acetyl; DANZ, dansylaziridine; DDPM, N-(4-dimethylamino-3-5-dinitrophenyl)maleimide; DACM, di-methylamino-4-maleimidostilbene; DMSM, N-(2,5-dimethoxystiben-4-yl)-maleimide; DNP, 2,4-dinitrophenyl; ε-A, 1,N⁶-ethenoadenosine; EIA, 5-(iodoacetetamido)eosin; EITC, eosin-5-isothiocyanate; ENAI, eosin N-acetylimidazole; EM, eosin maleimide; ErITC, erythrosin-5'-isothiocyanate; ETSC, eosin thiosemicarbazide; F₂DPB, 1,5-difluoro-2,4'-dinitrobenzene; F₂DPS, 4,4'-difluoro-3,3'-dinitrophenylsulphone; FITC, fluorescein N-acetylimidazole; FTS, fluorescein thiosemicarbazide; IAANS; 2-((4'-iodoacetamido)anilino)naphthalene-6-sulphonic acid; IAEDANS, 5-(2-((iodoacetyl)amino)ethylamino)-naphthlene-1-sulphonic acid; IAF, 5-iodoacetamidofluorescein; IANBD, N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa1,3,diazole; IPM, 3(4-isothiocyanatophenyl)7-diethyl-4-methylcoumarin; ISA, 4-

- 7 -

(iodoacetamido)salicylic acid;LRH, lissaminerho-2,1,3-benzoxadiazol-4-yl; NCP, N-cyclohexyl-N'-(1-pyrenyl)carbodiimide; ODR, octadecylrhodamine; PM, N-(1-pyrene)-maleimide; SRHsulphurhodamine; TMR, tetramethylrhodamine; TNP, trinitrophenyl; TR, Texas red.

5 from: Wu, P. and Brand, L. 1994. Anal. Biochem. 218; 1-13.

The specificity of soluble peptide libraries have been determined.^{15,16} Berman et al. described¹⁶ an HPLC mass spectrometry technique in which 6 mixtures of 128 peptides were synthesised which were N-terminally labelled with the
10 Dnp group in order to allow UV monitoring on the HPLC. The disadvantage of this approach is that each assay mixture has to be individually analysed, because no fluorogenic substrate is revealed, and that the effective concentration of each separate component is limited by the
15 size of the mixture because of overall solubility factors.

Drevin et al.¹⁷ have suggested the use of individually synthesised fluorogenic substrates for the determination of enzyme activity using a chromophore which chelates lanthanide ions. Garmann and Phillips have suggested the
20 use of FRET substrates in which the fluorogenic and quencher moieties are attached via thiol or amino functional groups after the peptide has been synthesised, but this has the disadvantage that they are not in library form and that these functional amino and thiol groups need
25 to be selectively revealed after the peptide has been synthesised. Wang et al. have suggested the use of the EDANS and DABCYL fluoescor and quencher pairing for the individual synthesis of substrates for proteolytic enzymes.

- 8 -

The above methods which have used FRET techniques for the mapping of the active site around a specific protease suffer from one or more of the following disadvantages:

- i. because of general aqueous insolubility they do not produce mixtures of compounds in a form suitable for high throughput screening in aqueous solution.
- ii. the derivatised compounds cannot be prepared in combinatorial library form using solid phase techniques.
- iii. the mixtures which have been used^{8,9} were not self-decoding, and needed time-consuming deconvolutive resynthesis for identification of the active molecules.

Kinases

Protein kinases are intracellular enzymes that play key roles in cell growth, differentiation and inter-cell communication. Aberrant protein kinase activity has been implicated in many disease states including several forms of cancer and severe-combined immunodeficiency disease. All serine/threonine and tyrosine protein kinases have a region of approximately 300 amino acids known as the catalytic subunit which has evolved from a common ancestor kinase (Hunter et al, 1991). Crystal structure determination of several kinases has shown that they all have a common bi-lobal structure. The amino-terminal part of the subunit encodes a small lobe responsible for the binding of ATP, whereas the carboxy-terminal residues encode a larger lobe important for protein substrate binding. In the tertiary structure of the active kinase, both the ATP and the protein substrate binding sites are

- 9 -

brought together allowing transfer of the ATP γ -phosphate to the amino acid acceptor on the protein substrate. The protein/peptide binding groove stretches across the face of the large lobe between two α -helices and under the small lobe. This groove therefore contains the residues important for substrate specificity of the kinase. Protein kinases are arranged in kinase cascades within the cell, providing the ability for signal amplification in post-transduction pathways. This amplification relies on the upstream kinase specifically activating its downstream partner. For this reason, protein kinases have developed remarkable substrate specificities which prevent unwanted crosstalk between different kinase cascades. We believe that such substrate specificity can be exploited in the design of selective protein kinase inhibitors.

Existing protein kinase inhibitors

Non-peptide inhibitors

Most available non-peptide protein kinase inhibitors do not target the substrate binding region, but compete with ATP for enzyme binding. These inhibitors can be engineered using conventional medicinal chemistry to demonstrate specific enzyme selectivity. An example of this strategy was the modification of the fungal metabolite staurosporine, a general protein kinase inhibitor, to the bis-indolyl-maleimides Ro 31-7549 and Ro 31-8425 (fig. 17) which are selective protein kinase C inhibitors (Muid et al, 1991). Unfortunately, the potency of ATP antagonist inhibitors can be dramatically reduced in certain intracellular compartments due to the high (millimolar) levels of ATP.

- 10 -

The aromatic compound erbstatin (fig. 18) produced by certain Streptomyces strains was identified in screens for reversal of protein tyrosine kinase-induced cell transformation. Erbstatin was subsequently shown to inhibit the EGFR kinase *in vitro* with a k_i of 5.58 μM and typical lineweaver-Burke competitive kinetics against a peptide substrate, while remaining non-competitive with ATP (Umezawa and Imoto, 1991). The compound is readily inactivated in calf serum and so could not be considered as a serious candidate for therapeutic use. Attempts have been made to both increase the stability of erbstatin, by replacement of the N-formyl moiety, and bias the inhibition towards specific tyrosine kinases using a systematic modification of all parts of the molecule. These synthetic erbstatin derivatives are known as tyrphostins (tyrosine phosphorylation inhibitors) and are mainly used as tools in enzyme/signal transduction research, but have had limited success in animal models of disease (see Levitzki and Gazit, 1995 for an extensive review).

Pseudosubstrate inhibitors

Research into the structure and function of protein kinases uncovered a natural method of regulating catalytic activity known as pseudosubstrate inhibition. This method uses sequences, either on the same molecule as the catalytic site (protein kinase C) or on a regulatory subunit molecule (cyclic cAMP-dependent protein kinase) that bind into the active site and inhibit kinase activity. These sequences do not have a phospho-acceptor residue, but modification of a single specific residue to

- 11 -

a phospho-acceptor results in the formation of a good substrate sequence. It is for this reason that the sequences are known as pseudosubstrates. Peptides based on pseudosubstrate motifs have been used as tools for inhibition of specific proteins kinases such as cyclic cAMP-dependent protein kinase (PKA), protein kinase C (PKC), myosin light chain kinase (MLCK) and calmodulin-dependent protein kinase II (Kemp et al, 1994). Pseudosubstrate peptides of less than 20 amino acids have been shown to be potent low nanomolar inhibitors in vitro with pseudosubstrate-based peptides of six amino acids inhibiting protein kinases at less than one micromolar (Kemp et al, 1991).

It is clear that there is scope for a small molecular weight inhibitor of protein kinases that competes with substrate for binding to the active site. A rational and peptide proven approach would be to base these inhibitors on substrate molecules which can specifically access the catalytic site. By focusing on pseudosubstrates, this approach would also have the advantage of "in-built" specificity, an element which is generally missing when leads are identified from random screening approaches.

Protein kinase inhibitors in disease treatment

Currently, there are no specific protein kinase inhibitors available for clinical use. Nevertheless, the potential for such compounds is clear with every major pharmaceutical company having projects for kinase inhibition in a number of therapeutic areas, most notably oncology, autoimmunity and transplant rejection.

- 12 -

Prototypic kinase inhibitor compounds are widely available from many companies, and are used as tools for *in vitro* signal transduction research. Several have formed the basis for extensive medicinal chemistry programmes designed to engineer both selectivity and enhanced activity into these compounds. A number of examples have been reported which indicate that this strategy has had some success in producing compounds active both *in vitro* within cell assay systems, and in animal models of disease. Staurosporine analogues (CGP41251 and UCN-01) have been used to show anti-tumour activity *in vivo* (Meyer et al, 1989; Akinagaka et al, 1991) and selective PKC inhibitors have been shown to work in animal models of acute inflammation (Bradshaw et al, 1993). Moreover, the BMN tyrphostin AG490 has been shown to inhibit lymphoblastic leukaemia growth in animal models, correlating with its ability to inhibit the non-receptor intracellular tyrosine kinase JAK-2 (Meydan et al, 1996). These promising preclinical studies have yet to be translated into the clinic, and it is possible that unforeseen toxicological problems, perhaps related to compound specificity, could be delaying their progress.

During the past few years, there has been an explosion of knowledge relating to kinase structure, function and activity. New kinases have also been identified, some of which have a sufficiently restricted cellular distribution that one could envisage that a specific inhibitor would have selective effects e.g. a ZAP70 inhibitor would selectively inhibit activation of T cells and, to a lesser extent, NK cells. Together, these aspects offer the

- 13 -

promise of new approaches for the development of kinase inhibitors to treat a range of conditions.

Method of Protein Kinase Inhibitor Design

Generation of initial substrate information

5 A technique has recently been developed by L. Cantley's laboratory to provide, consensus peptide kinase substrate information (Songyang et al, 1994). Firstly, a degenerate peptide library of peptides with a central phospho-acceptor such as tyrosine or serine/threonine flanked by
10 four unknown amino acids on each side is synthesised. The library is then phosphorylated by the protein kinase of interest and phosphorylated peptides isolated by DEAE-sephacel and ferric chelation chromatography. The phosphopeptide mixture is then sequenced and the frequency
15 of each amino acid at every position -4 to +4 assessed to give a preferred substrate sequence. These studies have yielded consensus substrate information, and do not allow a detailed analysis of particular preferences for neighbouring residue interactions. Similarly, the analysis
20 was performed solely with natural amino acids. Filamentous phage are now also being used to generate substrate information (Miami, Biotechnology Conference, 1996). Substrate information can also be obtained from knowledge of the physiological substrates for the kinase
25 in vivo.

Description of the Drawings

- 14 -

Figures 1 to 14 inclusive exemplify component distributions in the plates of a library matrix;

Figure 15 illustrates a reaction scheme for production of compound number 4: Boc-Val-Ala-Leu-H wherein

- 5 i. isobutylchloroformate, N-methylmorpholine, then N,O-dimethylhydroxylamine HCl, THF.
- ii. HCl, dioxan. iii. isobutylchloroformate, N-methylmorpholine, then Boc-Ala-OH, THF.
- iv. HCl, dioxan. V. Boc-Val-Osuc, N-methylmorpholine,
10 DMF. Vi. LAH;

Figure 16 illustrates a reaction scheme for production of active inhibitors of *Der PI*.

Figure 17 shows the molecular structure of the Roche protein kinase C inhibitors. A; Ro 31-8425/002, 3-[8(RS)-(aminomethyl)-6,7,8,9-tetrahydropyridol[1,2-a]indol-10-yl]-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride. B; Ro 31-7549/001, 3-[1-(3-aminopropyl)-3-indolyl]-4-(1-methyl-3-indolyl)-1H-pyrrole-2, 5-dione hydrochloride.

20 Figure 18 shows the molecular structure of the protein tyrosine kinase inhibitor erbstatin, isolated from *Streptomyces* MH435-hF3.

Brief Description of the Invention

- 15 -

The present invention relates to the field of apparatus and methods which provide the rapid generation of structure-activity relationships using auto-deconvoluting combinatorial libraries, which facilitate the invention of novel active compounds.

We describe herein apparatus and methods which can be used for the rapid generation of structure-activity relationship (SAR) data and, therefore, the characterisation of the active motif of any group of compounds.

The invention provides two orthogonal sets of mixtures of compounds in solution providing two complementary combinatorial libraries indexed in two dimensions for autodeconvolution. These are referred to as primary and secondary libraries.

The general concept of two orthogonal sets of mixtures indexed in two dimensions can be applied to various permutations of numbers of wells, plate layout, number of permutations per mixture etc. However, according to the invention the numerical interrelationship is defined as indicated below for libraries containing compounds with four variable groups B, C, D and E.

General Deconvolution Formulae

-Bb-Cc-Dd-n(Ee) - (I)

- 16 -

- 1) Primary and Secondary plates preferably have the same number of compounds per well [X]: otherwise there are two values, having X_p and X_s respectively.
- 2) The primary library comprises [np] plates.

5 If $R_p.C_p = R_s.C_s$, then the number of plates in the secondary library is also [np]. If not, the number of plates in the secondary library [ns] is:

$$ns = \frac{R_p.C_p}{R_s.C_s} . np$$

10 eg. A primary library of $np=4$, $R_p=8$, $C_p=10$ can be set out in an $R_s=4$, $C_s=5$ secondary library with the number of plates equal to:

$$ns = \frac{8 \times 10}{4 \times 5} . np$$

15 = 16 plates.

Number of compounds per well

$$-Bb-Cc-Dd-np(Ee) - \quad (1)$$

Number of possible combinations [k] is given by:

- 17 -

$$k = b.c.d.np.e \quad (2)$$

When number of wells on a plate = [N], number of compounds per well = [X] and number of plates = [np]:

$$k = X.N.np \quad (3)$$

5 However, number of wells [N] is also defined by the number of rows [Rp] and number of columns [Cp]:

$$N = Rp.Cp \quad (4)$$

Combining (3) and (4):

$$k = X.Rp.Cp.np \quad (5)$$

10 Combining (2) and (5):

$$b.c.d.np.e = X.Rp.Cp.np \quad (6)$$

Cancelling [np] from both sides of the equation:

$$b.c.d.e = X.Rp.Cp \quad (7)$$

15 Two of the variables (e.g. b.c) on the left side of the equation must each be equal in number to the number of columns [Cp], whilst a remaining variable (e.g. d) on the

- 18 -

left side must be equal in number to the number of rows
[Rp]. So:

$$[Cp]^2 \cdot Rp \cdot e = X \cdot Rp \cdot Cp \quad (8)$$

Cancelling [Cp] and [Rp] from both sides of the equation:

$$5 \quad Cp \cdot e = X \quad (9)$$

where [e] is the number of variants along a fixed row; and

if $Rp=Cp$, then $Rp \cdot e = X$.

Example

for a 10 x 10 x 8 x 8 format over 4 plates:

$$10 \quad np \cdot e = 8 \quad \Rightarrow \quad e = 2$$

$$10 \times 2 = X$$

$$X = 20.$$


- 19 -

From an understanding of the general deconvolution formulae shown above, those skilled in the art will readily appreciate that the advantageous results of self-deconvolution according to the invention are obtainable
5 utilising a number of different arrangements of wells, plate layouts, mixtures etc and that such variants on the preferred embodiment illustrated herein are intended to be within the scope of the present invention.


The molecules may be cyclic or alicyclic. They may be
10 linear or cyclic on the same structure

B-C-D-E


or



or BCDE can be on a central scaffold (linear or cyclic)




or



15

or one of the residues can be the backbone

- 20 -



Where the symbol -B-C-D-E- or -B-C-D-nE- is used herein,
5 it is to be understood to include all of these linear and
cyclic variants within its definition.

At least one but not all the bonds between B, C, D, E need
to be scissile. Non scissile bonds may include
sulphonamide, urea, aminomethylene.

10 Several non-limiting examples of "scaffold" molecules are
shown in Table 2, in which substituents R₁-R₄ correspond to
possible variable groups B, C, D and E.

In a first aspect the invention provides novel compounds
represented by the formula A-B-C-D-nE-F [I] in which;

15 A represents a fluoescor internally quenched by F;

B, C, D, and E represent groups such that the scissile
bond between any two of these groups is a suitable bond;

F represents a quencher capable of internally quenching
the fluoescor A; and

20 n represents an integer between 1 and 4 inclusive.

- 21 -

In some embodiments the suitable bond is an unsubstituted amide bond (see Example 1); in other embodiments the suitable bond is an ester bond (see Example 2).

In preferred embodiments B, C, D, E are amino acids or hydroxy acids. That is a molecule with an amine or hydroxy terminus and a carboxylic acid terminus. The amine/hydroxy group may be positioned on the same carbon atom or separated by a number of atoms and atom types.


In a second aspect the invention provides a combinatorial library of FRET compounds comprising a mixture of compounds of formula [I].

In a third aspect the invention provides for the use of such a combinatorial FRET library in a method which provides rapid generation of structure-activity relationships (SAR) which comprises detection and measurement of proteolytic enzyme activity by carrying out an assay with a library of combinatorial FRET (fluorescence resonance energy transfer) molecules to find a substrate or substrates for the enzyme. According to this method an identified substrate can be synthesised and used in biological assay for proteolytic enzymes. Novel substrates are included in the scope of the invention.

In a forth aspect the invention provides for the use of such a combinatorial FRET library in a method for detection and measurement of proteolytic enzyme activity against compounds of the library.









- 22 -

In a fifth aspect the invention provides a method which comprises the identification of an enzyme inhibitor or inhibitors wherein a FRET compound which has been



- 23 -

TABLE 2



- 24 -

identified as a substrate is used in an inhibition assay with the enzyme separately against a panel of possible inhibitors.

In a sixth aspect the invention provides a set of compounds which comprises two complementary FRET compound libraries. Such a set will be referred to hereafter as "apparatus" because it allows for the screening or assay method for identifying substrates or inhibitors of proteolytic enzymes. This set of compounds constituting an apparatus is capable of providing an auto-deconvoluting combinatorial library as will be described below.

In a seventh aspect the invention provides a method of identifying and synthesising an inhibitor of a proteolytic enzyme which comprises detection and measurement of proteolytic enzyme activity by carrying out an assay with a library of combinatorial FRET (fluorescence resonance energy transfer) molecules, deconvoluting the library to find a substrate or substrates for the enzyme and synthesis of an inhibitor based on the substrate or substrates. The direct product of this method is one or more novel proteolytic enzyme inhibitors.

In an eighth aspect the invention provides an inhibition assay which uses a FRET molecule, which has been identified as a substrate for the enzyme, wherein the molecule is assayed with the enzyme separately against a panel of possible inhibitors.

- 25 -

In a ninth aspect the invention provides a complementary pair of compound libraries L1 and L2 which constitute a set containing compounds of formula:

Aa-Bb-Cc-Dd-n(Ee)-Ff-Gg

5 giving $a \times b \times c \times d \times e \times f \times g = M_n$ compounds in each library, there being a predetermined number (P1, P2) of mixtures each consisting of a predetermined number (Q1, Q2) of individual identifiable compounds in each library, wherein both L1 and L2 contain the same M_n compounds, but
10 wherein any two compounds which are found together in one mixture of Q1 compounds of L1 are not found together in any one of the P2 mixtures of L2.

In a tenth aspect the invention provides a method of screening for enzymic activity using the libraries L1, L2
15 described above in which the P1 mixtures of L1 and the P2 mixtures of L2 are each placed separately into individual wells of well plates, the well plates having wells arranged in a format adapted to allow deduction of a unique active compound formula from the presence of
20 activity in one well of L1 and one well of L2.

The apparatus of the invention preferably comprises two complementary compound libraries, L1 and L2, each containing $n \times 1600$ compounds of the invention, of the type A-B₁₋₁₀-C₁₋₁₀-D₁₋₈-n(E₁₋₂)-F-G [II], in which:

- 26 -

A = a fluorescor internally quenched by F, preferably an unsubstituted or substituted anthranilic acid derivative, connected by an amide bond to B

5 B, C, D, E, are natural or unnatural amino acid residues connected together by suitable bonds, although B, C, D and E can be any set of groups, provided that the scissile bond between D-E is an unsubstituted bond.

F = a quencher capable of internally quenching the fluorescor A, preferably an unsubstituted or substituted
10 3-nitrotyrosine derivative.

G = optionally present and is a hydrophilic moiety, preferably an aspartyl amide moiety. If present, G advantageously ensures that all compounds in the library are imparted with aqueous solubility. Also, G should not
15 be a substrate for any type of enzyme.

n = any integer between 1 and 4 inclusive.

In an alternative, the scissile bond could be between B-C or C-D.

(Note that A and F herein correspond generally and
20 respectively to moieties F and Q of the prior art referred to above).

The numbers represented in subscript following residues B, C, D and E refer to the number of possibilities from which those residues are selected. Thus, by way of illustrative
25 example, A-B_{1,5}-C-D-E_{1,2}-F-G represents a mixture of the following ten compounds:

- 27 -

A-B₁-C-D-E₁-F-G
 A-B₂-C-D-E₁-F-G
 A-B₃-C-D-E₁-F-G
 A-B₄-C-D-E₁-F-G
 5 A-B₅-C-D-E₁-F-G
 A-B₁-C-D-E₂-F-G
 A-B₁-C-D-E₂-F-G
 A-B₃-C-D-E₂-F-G
 A-B₄-C-D-E₂-F-G
 10 A-B₅-C-D-E₂-F-G

The general combinatorial formula for each library can be expressed as:

$$A_1-B_{10}-C_{10}-D_8-n(E_2)-F_1-G_1 \quad [III]$$

providing $1 \times 10 \times 10 \times 8 \times n \times 2 \times 1 \times 1 = 1600n$
 15 compounds.

Both compound libraries, L1 and L2, of the above type are
 synthesized using solid phase techniques using the
 Multipin approach²⁴ such that each library contains 1600n
 compounds as 80n mixtures of 20 distinct, identifiable
 20 compounds. These 20 component mixtures are then placed
 separately into each of 80 wells of a 96 well plate (the
 other two lanes are used for control experiments) and then
 screened against a known quantity of the protease.

Thus it is an important part of the invention that
 25 regardless of the number of compounds contained in the two

- 28 -

libraries L1 and L2 (e.g. in the preferred embodiment:
1600n, where n = any integer between 1 and 4) the
libraries themselves are complementary and amenable to
deconvolution without recourse to resynthesis. It is also
5 an important part of the invention that the library matrix
has been especially formatted so that the most important
site pairings P₂ and P₁ for proteolytic enzymes can be
identified immediately without recourse to resynthesis.

Those compounds of the type A-B-C-D-E-F-G that are the
10 better substrates for the protease will be cleaved, and
can be readily identified because the fluorescor, A, will
be cleaved from its nearby quencher F, in a time dependent
manner which can be easily quantified. The fluorescent
quenching by F of A only occurs when the two are in nearby
15 proximity, normally within 30 angstrom units. Hence
cleavage of a scissile bond (e.g. the scissile bond D-E)
allows F to move further away from A and thus allow A to
fluoresce when excited by light of the correct wavelength.

1. In this manner the most active compound can be
20 rapidly identified without the need for further
resynthesis and deconvolution. Moreover, the wells
that show the most rapid development of fluorescence
can also be analysed by mass spectrometry, since by
comparison with the original mixture, the identity of
25 the most efficient substrate can be found by its
disappearance into its two component parts, e.g A-B-
C-D and E-F-G.

- 29 -

Hence the problem of library deconvolution can be overcome and the most active substrate for the enzyme can be rapidly identified.

In addition, after the initial treatment of the
5 proteolytic enzyme with the library mixtures, L1 and L2, the residual enzymatic activity in each well can be quantified by the addition of the most potent fluorogenic substrate for the enzyme, S1, which is found in the 16xn compound library. Because of the nature of the library
10 design this can be quickly prepared and purified. If there is no appearance of increased fluorescence with the known substrate, S1, then the presence of an enzyme inhibitor can be inferred, which again can be quickly identified without the need for resynthesis.

15 The general description of the library layout will now be described with reference to figures 1 to 14.

For example, when $n=1$ and the library contains 1600 compounds, in the first column of the first row (A1) (Fig.1) in the first plate (P1) of the library L1,
20 (hereinafter designated as location A1,P1,L1) there will be one C component, C_1 , one D component, D_1 , the ten B components and the two E components (E_1 and E_2) (Fig. 2). In the tenth column of the first row (A10) in the first plate (P1) of the library L1, (hereinafter designated as
25 location A10,P1,L1) there will be one C component, C_{10} , one D component, D_1 , the ten B components and the two E components (E_1 and E_2). In the tenth column of the eighth row (H10) in the first plate (P1) of the library L1,

- 30 -

5

10

15

20

25

In the first column of the first row (A1) of the second plate (P2) of the library, L2, (hereinafter designated as location A1,P2,L2), there will be ten C components, two D components (D₁ and D₂), one B component, B₁, and one E

- 31 -

component, E_1 (Fig. 4). In the tenth column of the first row (A10) of the second plate (P2) of the library, L2, (hereinafter designated as location A10,P2,L2), there will be ten C components, two D components (D_3 and D_4), one B component, B_{10} , and one E component, E_1 . In the first column of the second row (B1) of the second plate (P2) of the library, L2, (hereinafter designated as location B1,P2,L2), there will be ten C components, two D components (D_3 and D_4), one B component, B_1 , and one E component, E_2 . In the tenth column of the second row (B10) of the second plate (P2) of the library, L2, (B10,P2,L2), there will be ten C components, two D components (D_3 and D_4), one B component, B_{10} , and one E component, E_2 . Hence only the first two rows are used to accommodate 400 compounds in total.

In the first column of the first row (A1) of the third plate (P3) of the library, L2, (hereinafter designated as location A1,P3,L2), there will be ten C components, two D components (D_5 and D_6), one B component, B_1 , and one E component, E_1 (Fig 5). In the tenth column of the first row (A10) of the third plate (P3) of the library, L2, (hereinafter designated as location A10,P3,L2), there will be ten C components, two D components (D_5 and D_6), one B component, B_{10} , and one E component, E_1 . In the first column of the second row (B1) of the third plate (P3) of the library, L2, (hereinafter designated as location B1,P3,L2), there will be ten C components, two D components (D_5 and D_6), one B component, B_1 , and one E component, E_2 . In the tenth column of the second row (B10) of the third plate (P3) of the library, L2, (B10,P3,L2), there will be ten C components, two D components (D_5 and

- 32 -


D_6), one B component, B_{10} , and one E component, E_2 . Hence only the first two rows are used to accommodate 400 compounds in total.

In the first column of the first row (A1) of the fourth plate (P4) of the library, L2, (hereinafter designated as location A1,P4,L2), there will be ten C components, two D components (D_7 and D_8), one B component, B_1 , and one E component, E_1 (Fig. 6). In the tenth column of the first row (A10) of the fourth plate (P4) of the library, L2, (hereinafter designated as location A10,P4,L2), there will be ten C components, two D components (D_7 and D_8), one B component, B_{10} , and one E component, E_1 . In the first column of the second row (B1) of the fourth plate (P4) of the library, L2, (hereinafter designated as location B1,P4,L2), there will be ten C components, two D components (D_7 and D_8), one B component, B_1 , and one E component, E_2 . In the tenth column of the second row (B10) of the fourth plate (P4) of the library, L2, (B10,P4,L2), there will be ten C components, two D components (D_7 and D_8), one B component, B_{10} , and one E component, E_2 . Hence only the first two rows are used to accommodate 400 compounds in total.

In this fashion two complementary libraries, L1 and L2 are prepared. In library, L1, each of the 80 of wells contains a mixture of 20 components providing 1600 compounds for screening. In library, L2, four plates are used in which only the first two rows are employed, providing 20 wells of 20 components per well per plate, and furnishing the same 1600 compounds as are present in

- 34 -

The confirmation of the substrate as



should be provided by non-fluorescence of P1 L2, P3 L2 and P4 L2 which all contain $-B_2-C_3-X-E_1-$ where X is not D_4 .

5 In practice it is likely that more than one sequence will result in a substrate. Information as to which positions B-C-D-E- are sensitive to change (i.e. require a specific group) and which are insensitive (i.e. can tolerate more than one choice of group) in the context of the whole
10 sequence gives valuable SAR data which can be used to model and/or synthesise related compounds.

In analogous examples, where separately $n=2, 3$ or 4 , extra plates are constructed in library L1 format to accommodate the component pairs E_1 and E_4 ($n=2$), E_5 and E_6 ($n=3$), and
15 E_7 and E_8 ($n=4$), respectively. For the respective deconvolution libraries of the type, L2, the respective rows in the plates P1, P2, P3, and P4, are increasingly filled with the paired components D_1 and D_2 , D_3 and D_4 , and D_5 and D_6 , and D_7 and D_8 , respectively.

20 For example, when $n=3$, and the library contains 4800 compounds, in the first column of the first row (A1) in the first plate (P1) of the library L1, (hereinafter designated as location A1,P1,L1) there will be one C component, C_1 , one D component, D_1 , the ten B components
25 and the two E components (E_1 and E_2). In the tenth column

- 35 -

of the first row (A10) in the first plate (P1) of the library L1, (hereinafter designated as location A10,P1,L1) there will be one C component, C_{10} , one D component, D_1 , the ten B components and the two E components (E_1 and E_2).
5 In the tenth column of the eighth row (H10) in the first plate (P1) of the library L1, (hereinafter designated as location H10,P1,L1) there will be one C component, C_{10} , one D component, D_8 , the ten B components and the two E components (E_1 and E_2). Hence 1600 components are present
10 in the one plate, because the 80 wells each contain 20 components.

In the first column of the first row (A1) in the second plate (P2) of the library L1, (hereinafter designated as location A1,P2,L1) there will be one C component, C_1 , one
15 D component, D_1 , the ten B components and the two E components (E_3 and E_4). In the tenth column of the first row (A10) in the second plate (P2) of the library L1, (hereinafter designated as location A10,P2,L1) there will be one C component, C_{10} , one D component, D_1 , the ten B
20 components and the two E components (E_3 and E_4). In the tenth column of the eighth row (H10) in the second plate (P2) of the library L1, (hereinafter designated as location H10,P1,L1) there will be one C component, C_{10} , one D component, D_8 , the ten B components and the two E
25 components (E_3 and E_4). Hence 1600 components are present in the one plate, because the 80 wells each contain 20 components.

In the first column of the first row (A1) in the third plate (P3) of the library L1, (hereinafter designated as

- 36 -

location A1,P3,L1) there will be one C component, C_1 , one D component, D_1 , the ten B components and the two E components (E_5 and E_6). In the tenth column of the first row (A10) in the third plate (P3) of the library L1, (hereinafter designated as location A10,P3,L1) there will be one C component, C_{10} , one D component, D_1 , the ten B components and the two E components (E_5 and E_6). In the tenth column of the eighth row (H10) in the third plate (P3) of the library L1, (hereinafter designated as location H10,P3,L1) there will be one C component, C_{10} , one C component, C_8 , the ten B components and the two E components (E_5 and E_6). Hence 1600 components are present in the one plate, because the 80 wells each contain 20 components. In total the three plate, P1, P2 and P3, contain 1600 compounds/plate 4800 compounds in total.

For example, when $n = 4$, and the library contains 6400 compounds, in the first column of the first row (A1) in the first plate (P1) of the library L1, (hereinafter designated as location A1,P1,L1) there will be one C component, C_1 , one D component, D_1 , the ten B components and the two E components (E_1 and E_2) (Fig. 7). In the tenth column of the first row (A10) in the first plate (P1) of the library L1, (hereinafter designated as location A10,P1,L1) there will be one C component, C_{10} , one D component, D_1 , the ten B components and the two E components (E_1 and E_2). In the tenth column of the eighth row (H10) in the first plate (P1) of the library L1, (hereinafter designated as location H10,P1,L1) there will be one C component, C_{10} , one D component, D_8 , the ten B components and the two E components (E_1 and E_2). Hence all

- 37 -

1600 components are present in the one plate, because the 80 wells each contain 20 components.

In the first column of the first row (A1) in the second plate (P2) of the library L1, (hereinafter designated as location A1,P2,L1) there will be one C component, C₁, one D component, D₁, the ten B components and the two E components (E₃ and E₄) (Fig. 8). In the tenth column of the first row (A10) in the second plate (P2) of the library L1, (hereinafter designated as location A10,P2,L1) there will be one C component, C₁₀, one D component, D₁, the ten B components and the two E components (E₃ and E₄). In the tenth column of the eighth row (H10) in the second plate (P2) of the library L1, (hereinafter designated as location H10,P2,L1) there will be one C component, C₁₀, one D component, D₈, the ten B components and the two E components (E₃ and E₄).

In the first column of the first row (A1) in the third plate (P3) of the library L1, (hereinafter designated as location A1,P3,L1) there will be one C component, C₁, one D component, D₁, the ten B components and the two E components (E₅ and E₆) (Fig. 9). In the tenth column of the first row (A10) in the third plate (P3) of the library L1, (hereinafter designated as location A10,P3,L1) there will be one C component, C₁₀, one D component, D₁, the ten B components and the two E components (E₅ and E₆). In the tenth column of the eighth row (H10) in the third plate (P3) of the library L1, (hereinafter designated as location H10,P3,L1) there will be one C component, C₁₀, one

- 38 -

D component, D_8 , the ten B components and the two E components (E_5 and E_6).

In the first column of the first row (A_1) in the fourth plate (P_4) of the library L_1 , (hereinafter designated as location A_1, P_4, L_1) there will be one C component, C_1 , one
 5 D component, D_1 , the ten B components and the two E components (E_7 and E_8) (Fig. 10). Likewise, in the tenth column of the first row (A_{10}) in the fourth plate (P_4) of the library L_1 , (hereinafter designated as location
 10 A_{10}, P_4, L_1) there will be one C component, C_{10} , one D component, D_1 , the ten B components and the two E components (E_7 and E_8). In the tenth column of the eighth row (H_{10}) in the fourth plate (P_4) of the library L_1 ,
 (hereinafter designated as location H_{10}, P_4, L_1) there will
 15 be one C component, C_{10} , one D component, D_8 , the ten B components and the two E components (E_7 and E_8).

A second complementary library is synthesised as follows. In the first column of the first row (A_1) of the first plate (P_1) of the library, L_2 , (hereinafter designated as
 20 location A_1, P_1, L_2), there will be ten C components, two D components (D_1 and D_2), one B component, B_1 , and one E component, E_1 (Fig. 11). In the tenth column of the first row (A_{10}) of the first plate (P_1) of the library, L_2 ,
 (hereinafter designated as location A_{10}, P_1, L_2), there will
 25 be the ten C components, two D components (D_1 and D_2), one B component, B_{10} , and one E component, E_1 . In the first column of the eighth row (H_1) of the first plate (P_1) of the library, L_2 , (hereinafter designated as location
 H_1, P_1, L_2), there will be the ten C components, two D

- 39 -

components (D_1 and D_2), one B component, B_1 , and one E component, E_8 . In the tenth column of the eighth row (H_{10}) of the first plate (P_1) of the library, L_2 , (H_{10}, P_1, L_2) there will be the ten C components, two D components (D_1 and D_2), one B component, B_{10} , and one E component, E_8 . Hence the matrix containing all ten columns and all eight rows are used to accommodate 1600 compounds in total.

In the first column of the first row (A_1) of the second plate (P_2) of the library, L_2 , (hereinafter designated as location A_1, P_2, L_2), there will be ten C components, two D components (D_3 and D_4), one B component, B_1 , and one E component, E_1 (Fig. 12). In the tenth column of the first row (A_{10}) of the second plate (P_2) of the library, L_2 , (hereinafter designated as location A_{10}, P_2, L_2), there will be ten C components, two D components (D_3 and D_4), one B component, B_{10} , and one E component, E_1 . In the first column of the second row (B_1) of the second plate (P_2) of the library, L_2 , (hereinafter designated as location B_1, P_2, L_2), there will be ten C components, two D components (D_3 and D_4), one B component, B_1 , and one E component, E_2 . In the tenth column of the eighth row (H_{10}) of the second plate (P_2) of the library, L_2 , (H_{10}, P_2, L_2), there will be ten C components, two D components (D_3 and D_4), one B component, B_{10} , and one E component, E_8 .

In the first column of the first row (A_1) of the third plate (P_3) of the library, L_2 , (hereinafter designated as location A_1, P_3, L_2), there will be ten C components, two D components (D_5 and D_6), one B component, B_1 , and one E component, E_1 (Fig. 13). In the tenth column of the first

- 40 -

row (A10) of the third plate (P3) of the library, L2, (hereinafter designated as location A10,P3,L2), there will be ten C components, two D components (D_5 and D_6), one B component, B_{10} , and one E component, E_1 . In the first

5 column of the second row (B1) of the third plate (P3) of the library, L2, (hereinafter designated as location B1,P3,L2), there will be ten C components, two D components (D_5 and D_6), one B component, B_1 , and one E component, E_2 . In the tenth column of the eighth row (H10)

10 of the third plate (P3) of the library, L2, (H10,P3,L2), there will be ten C components, two D components (D_5 and D_6), one B component, B_{10} , and one E component, E_8 .

In the first column of the first row (A1) of the fourth plate (P4) of the library, L2, (hereinafter designated as

15 location A1,P4,L2), there will be ten C components, two D components (D_7 and D_8), one B component, B_1 , and one E component, E_1 (Fig.14). In the tenth column of the first row (A10) of the fourth plate (P4) of the library, L2, (hereinafter designated as location A10,P4,L2), there will

20 be ten C components, two D components (D_7 and D_8), one B component, B_{10} , and one E component, E_1 . In the first column of the second row (B1) of the fourth plate (P4) of the library, L2, (hereinafter designated as location B1,P4,L2), there will be ten C components, two D

25 components (D_7 and D_8), one B component, B_1 , and one E component, E_2 . In the tenth column of the eighth row (H10) of the fourth plate (P4) of the library, L2, (H10,P4,L2), there will be ten C components, two D components (D_7 and D_8), one B component, B_{10} , and one E component, E_8 .

- 41 -

The FRET strategy is based on the synthesis of two orthogonal sets of mixtures in solution. These solutions are each indexed in two dimensions. Thus the data from, for example, a protease scan identifies the most active compounds without the need for decoding or resynthesis. The positional preferences of sub-units (in this case amino acids) are optimised with respect to all other variant positions simultaneously. The synergistic relationship between all four positions is realised and both positive, beneficial and negative, deactivating data are generated. This leads to families (sub-populations) of substrates and their sub-unit preferences. The data can be fed into molecular modelling programs to generate pharmacophoric descriptors that encompass both the desirable features (from the positive data) and indicate undesirable interactions (from the negative data sets). Note that a one dimensional scan only indicates one position at a time as 'most active' and does not explore the synergistic relationship between positions.

The general methodology exemplified above with regard to the use of complementary combinatorial FRET libraries for the identification of proteolytic enzyme substrates, is equally applicable for identification of compounds from a library which interact with another active moiety. Combinatorial libraries of compounds containing four variable groups B, C, D and E can be produced and interactions with active moieties detected using suitable reporters or markers.

- 42 -

For example, the active moiety may be a protein kinase. Protein kinases include (but are not limited to) the following:

5 ZAP-70, Syk, p56^{lck}, p59^{fyn}, Yes, Hck, Src, Btk, Blk, Lyn, Raf, EGF kinase, Insulin receptor kinase, cyclin dependent kinases, Bcl-Abl, Ikb-kinase C-terminal kinases, Ikb N-terminal kinases, Jak kinases, MAP kinase kinases, MAP kinase kinase kinases, MAP kinases (Erks 1-3, p38 and Jun kinases), STAT family C-terminal serine/threonine kinases, 10 protein kinase A, protein kinase B, all protein kinase C isoforms.

The active interaction of a protein kinase with a compound in a library may be detected, for example, by radioactively labelled phosphorylation of the substrate in 15 the library.

Thus it is possible to identify peptide substrates of protein tyrosine kinase by phosphorylation of exogenous peptide substrates present in a library. The assay uses the transfer of ³²P from radiolabelled ATP to lysine-tagged 20 tyrosine-peptides substrate as a measure of kinase activity. The peptide binds to negatively charged membrane and is washed free of unincorporated [γ -³²P]-ATP. The detection of β -energy emission using a fluor-containing scintillant on a β -counter instrument provides 25 the measurement of peptide phosphorylation.

- 43 -

In another example the active moiety could be a glycosidase and the interaction would be with enzyme substrates in the library. In such a case a scissile bond between at least one of the groups B, C, D and E would be an acetal or glycosidic bond. The groups B, C, D and E could be selected from furanosides and pyranosides.

In another example the active moiety could be a nuclease. In such a case the scissile bond would be a phosphodiester bond and the groups B, C, D and E would be nucleotides.

The general methodology of the present invention can also be applied to the detection of an interaction between an active moiety such as a receptor and a library containing ligands for the receptor. Examples of receptor/ligand interactions are shown by way of non-limiting illustration below:

Chemokine receptor/chemokine i.e. CKR3/Eotaxin

SH3 domain/proline amino acid sequence i.e. Grb2/SOS peptide

WW domain/proline amino acid sequence i.e. Yap (Yes-associated protein)/RSV Gag protein

SH2 domain/phosphopeptide i.e. Grb2/LNK phosphopeptide

Lectin domain/ligand i.e. CD72/CD5.

Further more, combinatorial libraries of possible antigens or antigenic epitopes could be tested for interaction with an active antibody moiety.

- 44 -

The reporter or marker for detection of a reaction in receptor/ligand and antibody/antigen libraries could be similar. Suitable reporters are, for example, (but not limited to):

- 5 1. Biotin tag on the ligand using streptavidin-HRP for detection,
2. Alkaline phosphatase tag,
3. Radioisotope tag.

10 The invention will now be described by reference to the following examples.

Example 1: Cysteine Protease Inhibitors and Substrates

15 In this Example the proteolytic enzyme of interest is Der P1, which is found in house dust mite faeces. The example illustrates the synthesis of a number of FRET compounds in which the suitable bond is an unsubstituted amide bond, their use as a library for screening for potential substrates of Der P1, and subsequent identification and synthesis of active inhibitors of the enzyme.

Purification of Der pI.

20 Crude mite extract (~100mg, SmithKline-Beecham, U.K) was dissolved in 5mL Phosphate Buffered Saline (PBS; 50 mM

- 45 -

potassium phosphate; pH 7.4 containing 150 mM NaCl Der pI was purified by affinity column chromatography using 4C1 antibody (indoor Biotechnology, Deeside, U.K.) The crude preparation was mixed with ~2 mL of affinity resin for 2 h at 4°C and then washed with 2-3 volumes of PBS. Elution of bound protein was carried out using 5mM glycine containing 50%(v/v) ethylene glycol. Fractions(2.2 mL) were collected and neutralised with 0.8 mL of 0.2 M sodium phosphate buffer, pH 7.0. The fractions were pooled and dialysed overnight against 4 L PBS followed by a second dialysis against 2 L PBS for 2-3h. The total protein was concentrated as required by ultrafiltration (MacroSep; Flowgen, U.K.)

Synthesis of compounds

The compounds were synthesised using the Multipin approach^{25,26} using Fmoc-Rink amide Macro crowns (Chiron Mimotypes Pty., Ltd., 11 Duerdin Street, Clayton Victoria 3168, Australia) with a loading of 7 μ Moles.

The amino acid residues of each of the compounds were linked using amide bonds in a suitable form. The coupling chemistry employed is similar to that reported in the literature²⁷ for fluorenylmethoxycarbonyl protected amino acids and activated pentafluorophenyl esters, in which the side-chains are protected using acid labile protecting groups known to those skilled in the art, such as Boc- (for the -NH₂ of Lysine, -NH₂ of anthranilic acid and guanidino of arginine), tBu- (for the -OH groups of serine, threonine and tyrosine), t-Bu for the -COOH group

- 46 -

of Aspartic acid and Glutamic acid, Trityl- (for the Amide of Asparagine and Glutamine, and the amine functionality of the Histidine ring.

5 The N- α -fluorenylmethoxycarbonyl protecting group of the coupled residues were cleaved using 20% piperidine in dimethylformamide (DMF) for 30 minutes at 20° C. The coupling reactions for the free acids such as Boc-ABz-OH (Boc-2-aminobenzoic acid), and Fmoc-(3-nitro)tyrosine-OH were accomplished using 10 equivalents of a mixture of the
10 free acid (1 eq.) : TBTU (0.98 eq.) : HOBT (0.98 eq.) : N-methylmorpholine (1.96 eq.) in dimethylformamide (500 μ L) as solvent for 5 hours at 20° C. The other amino acids were coupled as their pentafluorophenyl esters²⁶ for 2-6 hours.

Hence, in order to couple approximately equal ratios of
15 each component in the mixture of the derivatised amino acids as their pentafluorophenyl esters, a solution of a total of 0.98 equivalents (relative to the amino group loading on the crown) of the mixture of amino acid pentafluorophenyl esters : HOBT (1 eq.) in DMF (500 μ L)
20 were coupled for 16 hours at 20° C. The pins were then washed well with DMF and then recoupled using the same mixture under the same conditions. A third coupling of 10 equivalents (relative to the amino group loading of the crown) for 2 hours in DMF was performed using this
25 coupling protocol with equimolar mixtures of the derivatised pentafluorophenyl esters of the amino acids in slightly less than 1 equivalent, it is possible to obtain approximately equal amounts of the coupled products to the crown. In this fashion the libraries are constructed with

- 47 -

20 compounds present on each crown. The compounds were cleaved from the crowns directly into the 80 designated wells of the desired 96 well plate. In the cleavage protocol each crown was treated with a mixture (600 μ L) containing trifluoroacetic acid (95%), triethylsilane (5%) for 2 hours at 20° C. The crowns were then washed with trifluoroacetic acid (500 μ L) and this was then combined with the cleavage solution.

The Fmoc-Rink amide Macro crowns (Chiron Mimotypes Pty., Ltd., 11 Duerdin Street, Clayton Victoria 3168, Australia) at 7 μ Mol loading per crown, were coupled with a 10 fold excess of a mixture containing L-Fmoc-Asp(O-t-Bu)-OH (1eq) using TBTU (0.98 eq) and N-methylmorpholine (1.96 eq.) in the presence of HOBt (0.98 eq.) in DMF at 0.14M concentration. After deblocking of the Fmoc group with 20% piperidine in DMF for 30 minutes and subsequent washing with DMF and then methanol, coupling of the Fmoc-(3-nitro)tyrosine-OH was accomplished using 10 equivalents of a mixture of the Fmoc-(3-nitro)tyrosine-OH (1 eq.) :TBTU (0.98 eq.) : HOBt (0.98 eq.) : N-methylmorpholine (1.96 eq.) in dimethylformamide as solvent at 0.14 M concentration for 5 hours at 20° C. Removal of the Fmoc group (*vide infra*) was followed by coupling of the mixtures of amino acids in the ratios outlined and under the conditions described (*vide infra*).

In a particular example the amino acids comprising group B include Ala, Val, Leu, Ser, Asn, Gln, Glu, Lys, Phe, Pro. The amino acids comprising group C include Ala, Val, Leu, Ser, Asn, Gln, Glu, Lys, Phe, Pro. The amino acids

- 48 -

comprising group D include Ala, Val, Ile, Leu, Nle, Ser, Glu, Phe. For $n=4$, the amino acids comprising group E include Ala, Val, Ile, Leu, Nle, Ser, Glu, Phe. Otherwise any selection from the amino acids can be made for $n=1, 2,$
5 or 3.

The plates containing the combined cleavage solutions and were then evaporated to dryness to yield the component mixtures using a rotary centrifuge ("SPEEDVAC", Savant Instruments Inc., Farmingdale, NY) at 800 rpm for 1 hour
10 at 20° C under a reduced pressure of 10^{-2} mmHg. Each component was then transferred to the final mother plate using a (50%: 45%: 5%) mixture of acetonitrile: water: acetic acid. The plates were then lyophilised to dryness using at 20° C under a reduced pressure of 10^{-2} mmHg, and
15 then stored at -20° C. In this fashion libraries of the type shown in Figures 2-14 were prepared.

In further detail, the Multipin approach which was employed is described below:

Multipin Synthesis Of Potential Substrates of Der pI

20 The 'Chiron' multipin kit consists of a standard 8 x 12 pin holder containing 96 'pin stems' to which are reversibly attached 'crowns'. The 'crowns' provide a reactive polymer surface upon which a growing peptide is anchored during solid phase peptide synthesis. Each crown
25 (the equivalent of the peptide-resin in standard solid phase synthesis) can be considered to be an independent

- 49 -

reactor by performing simultaneous synthesis in individual
1mL wells of industry standard 96 well plates. Each well,
and thus each crown, can be charged with a unique set of
reagents providing unique sequences to each crown. Common
5 steps such as washing or removal of N α protection can be
performed concomitantly.

Synthesis is based upon the use of N α -
fluorenylmethyloxycarbonyl (Fmoc) protected amino acids.
Side-chains of tri-functional amino acids are protected
10 with acid labile groups such as trityl or tert-butyl. The
addition of amino-acid residues to the growing peptide
chain, a process termed 'coupling' proceeds through the
utilisation of pre-formed pentafluorophenyl (pfp) esters
or activation of the free acid, using the reagents HBTU or
15 BOP in the presence of tertiary base (NMM) and HOBT as
catalyst.

The experimental techniques used are fully documented
(Maeji, N. J. Bray, A. M. Valerio, R. M. and Wang, W.,
Peptide Research, 8(1), 33-38, 1995 and Valerio, R. M.
20 Bray, A. M. and Maeji, N. J. *Int. J. Pept. Prot. Res*, 44,
158-165, 1994) and the main steps are briefly as follows.

General Methods

Preparation of Multipin Assembly

Whilst wearing standard plastic gloves, Fmoc-Rink Amide
25 derivitized macrocrowns are assembled (simply clipped)

- 50 -

onto stems and slotted into the 8 x 12 stem holder in the desired pattern for synthesis.

Removal of N α -Fmoc Protection

A 250mL solvent resistant bath is charged with 200 ml of a
5 20% piperidine/DMF solution. The multipin assembly is added and deprotection allowed to proceed for 30 minutes. The assembly is then removed and excess solvent removed by brief shaking. The assembly is then washed consecutively with (200mL each), DMF (5mins) and MeOH (5mins, 2mins,
10 2mins) and left to air dry for 15mins.

Quantitative UV Measurement of Fmoc Chromophore Release

A 1cm path length UV cell is charged with 1.2mL of a 20% piperidine/DMF solution and used to zero the absorbance of the UV spectrometer at a wavelength of 290nm. A UV
15 standard is then prepared consisting of 5.0mg Fmoc-Asp(OBut)-Pepsyn KA (0.08mmol/g) in 3.2mL of a 20% piperidine/DMF solution. This standard gives Abs₂₉₀ = 0.55-0.65 (at RT). An aliquot of the multipin deprotection solution is then diluted as appropriate to give a
20 theoretical Abs₂₉₀ = 0.6, and this value compared with the actual experimentally measured absorbance showing the efficiency of previous coupling reaction.

Coupling of amino-acid residues

- 51 -

Whilst the multipin assembly is drying, the appropriate $N\alpha$ -Fmoc amino acid pfp esters (10 equivalents calculated from the loading of each crown) and HOBt (10 equivalents) required for the particular round of coupling are

5 accurately weighed into suitable containers.

Alternatively, the appropriate $N\alpha$ -Fmoc amino acids (10 equivalents calculated from the loading of each crown), desired coupling agent e.g. HBTU (9.9 equivalents calculated from the loading of each crown) and activation

10 eg HOBt (9.9 equivalents calculated from the loading of each crown), NMM (19.9 equivalents calculated from the loading of each crown) are accurately weighed into suitable containers.

The protected and activated Fmoc amino acid derivatives

15 are then dissolved in DMF (500 μ l for each macrocrown, e.g. for 20 macrocrowns, 20 x 10eq x 7mmoles of derivative would be dissolved in 10 000 μ L DMF). The appropriate derivatives are then dispensed to the appropriate wells ready for commencement of the 'coupling cycle'. As a

20 standard, coupling reactions are allowed to proceed for 2-6 hours (depending upon nature of coupling e.g. Ala to Ala 2 hours Val to Leu 6 hours).

When coupling Fmoc amino-acid pentafluorophenyl esters, 10eq of derivative in DMF (400 μ l) with bromophenol blue

25 stock solution (100 μ l) is used for each macrocrown. This allows monitoring of the progress of the acylation reaction through the disappearance of the deep blue coloration of bromophenol blue in the presence of

- 52 -

unreacted amine to a pale yellow upon completion of acylation.

Preparation of Bromophenol Blue Stock Solution

5 Bromophenol blue (20mg) is dissolved in DMF (50mL) and HOBT (10mg) added.

Washing Following Coupling

If a 20% piperidine/DMF deprotection is to immediately follow the coupling cycle, then the multipin assembly is briefly shaken to remove excess solvent washed
10 consecutively with (200mL each), MeOH (5mins) and DMF (5mins) and deprotected (see above). If the multipin assembly is to be stored, then a full washing cycle consisting brief shaking then consecutive washes with (200mL each), DMF (5mins) and MeOH (5mins, 2mins, 2mins)
15 is performed.

Acidolytic Mediated Cleavage of Peptide-Pin Assembly

Acid mediated cleavage protocols are strictly performed in a fume hood. A polystyrene 96 well plate (1mL / well) is labelled, then the tare weight measured to the nearest mg.
20 Appropriate wells are then charged with a trifluoroacetic acid / triethylsilane (95:5, v/v, 600µl) cleavage solution, in a pattern corresponding to that of the multipin assembly to be cleaved.

- 53 -

The multipin assembly is added, the entire construct covered in tin foil and left for 2hrs. The multipin assembly is then added to another polystyrene 96 well plate (1mL /well) containing trifluoroacetic acid /
5 triethylsilane (95:5, v/v, 600 μ l) (as above) for 5 mins.

The cleaved assembly is washed with DMF (200 μ L, 5mins), MeOH (200 μ L, 5mins), the spent crowns removed and discarded, the stems removed and washed by sonication in methanol (1hr, RT).

10 Work up of Cleaved Peptides

The primary polystyrene cleavage plate (2hr cleavage) and the secondary polystyrene plate (5min wash) (see above) are then placed in the SpeedVac and the solvents removed (minimum drying rate) for 90mins.

15 The contents of the secondary polystyrene plate (see above) are transferred to their corresponding wells on the primary plate using an acetonitrile / water / acetic acid (50:45:5, v/v/v) solution (3 x 150 μ l) and the spent secondary plate discarded.

20 Analysis of Products

1.0 μ l of each well (see above) is diluted to 400 μ l with 0.1%aq TFA and analysed by HPLC-MS. Column Vydac C4 (214TP52, narrowbore, 21 x 250mm). Eluents :- Solvent A =

- 54 -

0.1%aq trifluoroacetic acid, Solvent B = acetonitrile /
10%A. Gradient :- 10-90% B in A over 27mins, 250ml / min,
215nm UV detection. The individual substrates described
below were prepared by the above methods and shown by
5 HPLC-MS to be >95% with the correct mass.

Final Lyophilisation of Peptides

The primary polystyrene plate (plus the washings from the
secondary plate) is covered with tin foil, held to the
plate with an elastic band. A pin prick is placed in the
10 foil directly above each well and the plate placed at
-80°C for 30mins. The plate is then lyophilised on the
'Heto freeze drier' overnight. Where appropriate
individual peptides were then weighed and dissolved to
10mM stock solutions in DMSO prior to biological
15 screening. Alternatively the 20 component mixture is
weighed and the peptide/20 component ratio is calculated.

Further coupling of amino acid residues was carried out
according to the multipin approach described above. Whilst
the multipin assembly was drying, the appropriate N α -Fmoc
20 amino acids (10 equivalents calculated from the loading of
each crown), HATU coupling agent (9.9 equivalents
calculated from the loading of each crown), HOAt catalyst
(9.9 equivalents calculated from the loading of each
crown) and DIPEA (19.9 equivalents calculated from the
25 loading of each crown) were accurately weighed into
suitable containers.

- 55 -

The protected N α -Fmoc amino acids and coupling agents were then dissolved in DMF (500 μ l for each macrocrown) and activated by the addition of DIPEA. The appropriate derivatives were then dispensed to their appropriate wells and as standard coupling to each macro crown was allowed to proceed for 2 hours.

When coupling particularly hindered amino acid residues such as N-Methyl, C α -Methyl or unusual amino acids (whose coupling efficiency is unknown) the coupling reaction was repeated, as standard, for a further 2 hours.

Substrates for Der pI

Using the general techniques described above, the following compounds were prepared and assayed as potential substrates against Der pI purified as described above.

15	Peptide [SEQ ID Nos. 1-76]	Measured K _m (μ M)
	Abz-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	12
	H-Val-Ala-Nle-Ser-TyrNO ₂ -Asp-NH ₂	NS
	H-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Ac-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
20	H-Val-Ala-Nle-Ser-Tyr(NO ₂)-NH ₂	NS
	H-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Ac-Val-Ala-Nle-Ser-Tyr(NO ₂)-NH ₂	NS
	Abz-Val-Ala-Nle-Ser-Tyr(NO ₂)-NH ₂	NM

WO 97/42216

PCT/GB97/01158

- 56 -

	Abz-Val-Ala-Nle-Ser-NH ₂	NM
	Abz-Val-Ala-Nle-Ser-Phe-Asp-NH ₂	NM
	Abz-Val-Ala-Nle-Ser-Tyr-Asp-NH ₂	NM
	Abz-Val-Ala-Nle-Ser-Ala-Asp-NH ₂	NM
5	Abz-Val-Ala-Nle-Ser-Lys-Asp-NH ₂	NM
	Abz-Val-Ala-Nle-Ser-eAHA-Asp-NH ₂	NM
	Abz-Ala-Nle-Ser-Tyr(NO ₂) -Asp-NH ₂	NM
	Abz-Nle-Ser-Tyr(NO ₂) -Asp-NH ₂	NS
	Bz-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
10	Bz(2-carboxy)-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
	Chex-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
	n-Bu-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
	Piv-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
	Bz-Val-Ala-Nle-Ser-Tyr(NO ₂) -NH ₂	NM ^a
15	Abz-Val-Ala-Lys-Ser-Tyr(NO ₂) -Asp-NH ₂	14
	Abz-Val-Ala-Gln-Ser-Tyr(NO ₂) -Asp-NH ₂	6
	Abz-Val-Ala-Thr-Ser-Tyr(NO ₂) -Asp-NH ₂	6
	Abz-Val-Ala-hLeu-Ser-Tyr(NO ₂) -Asp-NH ₂	4
	Abz-Val-Ala-Cha-Ser-Tyr(NO ₂) -Asp-NH ₂	5
20	Abz-Val-Ala-His-Ser-Tyr(NO ₂) -Asp-NH ₂	> 20
	Abz-Val-Ala-ACH-Ser-Tyr(NO ₂) -Asp-NH ₂	NS
	Abz-Val-Ala-DNle-Ser-Tyr(NO ₂) -Asp-NH ₂	NS
	Abz-Val-Ala-3pyr-Ser-Tyr(NO ₂) -Asp-NH ₂	10
	Abz-Val-Ala-Hyp-Ser-Tyr(NO ₂) -Asp-NH ₂	NS
25	Abz-Val-Ala-ACP-Ser-Tyr(NO ₂) -Asp-NH ₂	NS
	Abz-Val-Lys-hLeu-Ser-Tyr(NO ₂) -Asp-NH ₂	35
	Abz-Val-DAla-hLeu-Ser-Tyr(NO ₂) -Asp-NH ₂	NS

- 57 -

	Abz-Val-Tic-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-ACH-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-Met(O)-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	35
	Abz-Val-2Nal-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
5	Abz-Val-ACP-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-DLys-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-DGln-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-3pyr-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-Cha-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
10	Abz-DVal-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Gln-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	12
	Abz-Lys-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	>15
	Abz-Tic-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-ACH-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
15	Abz-Met(O)-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	20
	Abz-3pyr-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	>10
	Abz-2Nal-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	15
	Abz-Leu-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	18
	Abz-Cha-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	9
20	Abz-Bip-Ala-hLeu-Ser-Tyr(NO ₂)-Asp-NH ₂	2.5
	Abz-Bip-Ala-hLeu-Tyr-Tyr(NO ₂)-Asp-NH ₂	3
	Abz-Bip-Ala-hLeu-Leu-Tyr(NO ₂)-Asp-NH ₂	3.7
	Abz-Bip-Ala-hLeu-Lys-Tyr(NO ₂)-Asp-NH ₂	2
	Abz-Bip-Ala-hLeu-Asp-Tyr(NO ₂)-Asp-NH ₂	5.0
25	Abz-Bip-Ala-hLeu-Abu-Tyr(NO ₂)-Asp-NH ₂	1.7
	Abz-Bip-Ala-hLeu-Cha-Tyr(NO ₂)-Asp-NH ₂	2.5
	Abz-Bip-Ala-hLeu-Met(O)-Tyr(NO ₂)-Asp-NH ₂	5

- 58 -

	Abz-Bip-Ala-hLeu-Thr-Tyr(NO ₂)-Asp-NH ₂	2.5
	Abz-Bip-Ala-hLeu-3pyr-Tyr(NO ₂)-Asp-NH ₂	4
	Abz-Bip-Ala-hLeu-Bu ^t Gly-Tyr(NO ₂)-Asp-NH ₂	4
	Abz-Bip-Ala-hLeu-Hyp-Tyr(NO ₂)-Asp-NH ₂	4
5	Abz-Phe-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
	Abz-3.Pyr-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
	Abz-1.Naph-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	17
	Abz-2.Naph-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
	Abz-Tyr-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
10	Abz-Bip-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	10
	Abz-Lys-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	15
	Abz-Glu-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	20
	Abz-Leu-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NM
	Abz-Hyp-Val-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS

15 NS indicates that the peptide was not hydrolysed by Der pI.

NM indicates that the peptide was a substrate for Der pI, but the K_m was not measured.

20 NM^a indicates that the peptide was a substrate for Der pI, and its cleavage was followed by HPLC-MS showing hydrolysis to occur between-Nle-Ser-.

Ranked in order of cleavage rate :-Bz > n-But > Piv > Bz(2-carboxy) > Abz.

- 59 -

Coupling of amino acid residues was carried out according to the multipin approach described above. Whilst the multipin assembly was drying, the appropriate N α -Fmoc amino acids (10 equivalents calculated from the loading of each crown), HATU coupling agent (9.9 equivalents calculated from the loading of each crown), HOAt catalyst (9.9 equivalents calculated from the loading of each crown) and DIPEA (19.9 equivalents calculated from the loading of each crown) were accurately weighed into suitable containers.

The protected N α -Fmoc amino acids and coupling agents were then dissolved in DMF (500 μ l for each macrocrown) and activated by the addition of DIPEA. The appropriate derivatives were then dispensed to their appropriate wells and standard coupling to each macrocrown was allowed to proceed for 2 hours.

When coupling particularly hindered amino acid residues such as N-Methyl, C α -Methyl or unusual amino acids (whose coupling efficiency is unknown) the coupling reaction was repeated, as standard, for a further 2 hours.

The following sequences were synthesised in this way:

Peptide Sequence [SEQ ID Nos. 77-85] Measured Km(μ M)

Abz-Val-Ala-(NMe)Nle-Ser-Tyr(NO₂)-Asp-NH₂ NS

Abz-Val-(NMe)Ala-Nle-Ser-Tyr(NO₂)-Asp-NH₂ NS

- 60 -

	Abz-Val-Ala-Aib-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Val-Aib-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Deg-Ala-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	nBu-D.Ser-D.Nle-D.Ala-D.Val-p.Aba-NH ₂	NS
5	Bz-Val-Ala-Statine-Ser-eAha-NH ₂	NS
	Abz-p.Aba-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS
	Abz-Cmpi-Nle-Ser-Tyr(NO ₂)-Asp-NH ₂	NS

NS-Not Substrate: Not hydrolysed by *Der pI*

10 NM-Substrate but not measured: Substrate for *Der pI* but not measured.

Assay procedure

Each mixture of 20 compounds in the libraries of the apparatus described herein was screened at a concentration of 1.0 μ M per compound in an assay against the cysteinyl
 15 protease *Der pI*. The most active wells were identified by the rate of emission of fluorescence at 420 nm when the samples were irradiated at 320 nm. An analysis of the two complementary libraries showed that the best substrates for the enzyme were:

20 Abz-B-C-D-E-Tyr(NO₂)-Asp-NH₂

Where

B= Valine>Alanine, Glutamine, Leucine, Phenylalanine

C= Alanine>>Glutamine, or Lysine.

D= Leucine, Norleucine or Alanine>Serine

- 61 -

E=Serine

The best substrate was:

[SEQ ID:1] Abz-Val-Ala-Nle-Ser-Tyr(NO₂)-Asp-NH₂

This compound was then resynthesised as a single component
5 using the peptide synthesis methodology described herein.
The k_{cat}/K_m value for the pure substrate in the *Der pI* assay
was measured as $3.5 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$, and was considered to be
suitably high for use in a high throughput assay for the
general screening of inhibitors of *Der pI*.

10 High throughput assay development

Plate assays were carried out in 96 well plate format,
using 0.1 ug of *Der pI* per 100 μL assay volume in each
well and using 20 μM of the substrate. All assays were
performed in Assay Buffer (AB; 50 mM potassium phosphate,
15 pH 8.25 containing 1mM ethylenediaminetetraacetic acid
(EDTA) and 1mM dithiothreitol (DTT). The *Der pI* enzyme is
pre-activated by addition of DTT and this is incubated at
room temperature for 5 min. prior to initiation of the
assay. As an example for the screening methodology, each
20 well contains a 5 μL of a 20 μM solution of the test
compound in DMSO, 10 μL of a 200 μM aqueous solution of
the substrate, 2, and 85 μL of *Der pI* in AB is added to
initiate the reaction. Enzyme activity is monitored by
fluorescence using 320 nm for excitation and 420nm for the
25 emission wavelengths using a Labsystems Fluroskan Ascent

- 62 -

machine. Kinetic measurements were carried out using a Hitachi F-4500 Fluorescence Spectrophotometer.

Synthesis of inhibitors of Der pI

The best substrate described above was shown by HPLC-mass spectroscopic analysis of the enzyme/ assay solution, to be cleaved between the Norleucine-Serine amide bond. Replacement of the terminal Abz group by a series of derivatives (e.g. Boc-, Pivaloyl, Benzoyl, and 2- carboxy-Benzoyl) affected substrate activity and specificity for the Der pI enzyme. With this knowledge of the P₁-P₁' cleavage site and for the P₁-P₂-P₂-P₁ motif, the compound Boc-Val-Ala-Leu-H, 4, was synthesised as shown in Scheme 1a, figure 15.

Attachment of a suitable Michael acceptor such as CH=CH-CO₂Et, and -CH=CH-SO₂ Ph to the motif (Scheme 2, figure 16), provided active inhibitors of the enzyme with apparent IC₅₀ values of 50nM, 1000 nM and 100nM respectively.

Based on the sequence 4, a series of acyloxymethylketone compounds having active Der PI inhibitor activity was prepared. Details of the preparation and activity of this novel group of cysteine protease inhibitor compounds are discussed in co-pending International Application Publication Number WO97/04004.

Example 2: Viral Protease Inhibitors and Substrates

- 63 -

Design of Depsipeptides

Another suitable bond in a compound of general formula (I), (II) or (III) according to the invention is an ester bond to form a depsipeptide. The incorporation of
 5 depsipeptide substrates aided the identification of substrates for low reactivity viral proteases, such as viral serine proteases.

For example, substrates of the general formula



10 were produced.

However, a significant proportion of viral proteases only recognise substrate sequences larger than those represented by the general structure above. It is well acknowledged that by the very nature of action of a viral
 15 protease (function is to cleave immature viral proteins into the mature viral package) one automatically receives data concerning the natural substrate sites. Thus, the general structure above can be extended by introducing extra fixed amino-acids at appropriate sites. A logical
 20 extension would be to introduce the known P1-P1' cleavage site as the depsipeptide bond, then subsequently introduce the four variant positions following the standard format thus;

- 64 -

n [Abz-B₁₋₁₀-C₁₋₁₀-D₁₋₈-E₁₋₈-P1 y[COO]-P1'-Tyr(NO₂)-Asp-NH₂]

Furthermore, if these substrates again proved to be too small, one may use the known substrate sequences to introduce additional fixed positions. For instance, with
 5 Hepatitis NS3 protease it is known that the natural P6 position is a conserved acidic residue (aspartic or glutamic acid). Thus one could extend the above structure as detailed below.

n [Abz-P6-B₁₋₁₀-C₁₋₁₀-D₁₋₈-E₁₋₈-P1 y[COO]-P1'-Tyr(NO₂)-Asp-NH₂]

10 The novel methodology described herein greatly facilitates the invention of therapeutically useful proteolytic enzyme inhibitors and is commercially exploitable. This is because the best substrate motif for the proteolytic enzyme can be rapidly identified, and, since there exist
 15 in the literature a variety of ways for attaching motifs which react with the active site of a proteolytic enzyme, especially for aspartyl, metallo, serine and cysteinyl proteases, an enzyme inhibitor can be readily synthesised. Moreover, amide bond replacements or transition state
 20 mimetics can be incorporated into the molecule, which would be especially useful for the inhibition of aspartyl or metallo proteases.

The method described also facilitates the rapid development of a screening assay for novel protease
 25 inhibitors. The most potent fluorogenic substrate discovered by library screening can subsequently be used

- 65 -

for the detection of inhibitors of the particular proteolytic enzyme under scrutiny.

The presence of an inhibitor within the compound libraries described is readily detected by retreatment of the assay mixture with the most active fluorogenic substrate, which will allow the immediate measurement of the remaining proteolytic enzyme activity.

The invention provides self-decoding, combinatorial fluorogenic libraries, and it will greatly facilitate the design and invention of novel protease inhibitors because:

- i. The peptides of the library may have increased aqueous solubility in comparison to peptides containing similar and other fluorogenic and quencher groups.
- 15 ii. The peptides are stable to contaminating exopeptidases.
- iii. The self deconvolution method described, coupled with the continuous analysis of the rate of substrate cleavage data, allows the immediate identification of the most active binding motif contained within the substrate library.
- 20
- iv. The method allows for the rapid assessment of the enzyme assay mixture for any compounds in the library that are acting as enzyme inhibitors.
- 25

- 66 -

Example 3: Kinase Inhibitors and Substrates

As previously indicated, the present invention is a broadly applicable methodology and is not limited to the use of FRET libraries to detect protease
5 inhibitor/substrate compounds.

An example of another use of the invention is the detection of the interaction of a kinase with a substrate/inhibitor by monitoring radioactively labelled phosphorylation of compounds of complementary
10 combinatorial libraries.

The Identification of a ZAP-70 Tyrosine Kinase Inhibitor

ZAP-70 is a intracellular kinase essential for T-cell signal transduction from the T-cell antigen receptor. Mutations resulting in non-functional ZAP-70 kinase have
15 been observed in patients suffering from a severe combined immunodeficiency disease. Drug down-modulation of ZAP-70 kinase activity has therefore been seen by the major pharmaceutical companies as a potential method of down-regulating the immune system in an antigen-independent
20 manner. Such a drug could be used in both transplant treatment and as a therapy in autoimmune diseases.

Generation of ZAP-70 kinase catalytic domain

The full length protein ZAP-70 tyrosine kinase possesses amino-terminal tandem SH2 domains which allow enzyme

- 67 -

recruitment to phosphorylated tyrosine residues on the T cell antigen receptor, but are unnecessary for protein kinase catalytic activity. Removal of the SH2 domains results in a constitutively active, stable ZAP-70 kinase.

5 Specific oligonucleotide polymerase chain reaction (PCR) primers were used to amplify amino acids 308 to 619 and add a carboxy-terminal hexahistidine sequence using human Jurkat cDNA as a template. This amplicon was cloned into the baculoviral transfer vector pACUW51 (Pharmingen) and

10 recombinant baculovirus produced by homologous recombination in Sf9 insect cells.

CatZAP(H6) Purification

Low titre stocks of mixed CatZAP-70 baculovirus were used to infect sub-confluent monolayers of Sf9 cells. Cells

15 were harvested 3 days post-infection, washed in PBS and osmotic lysis performed immediately. Isolation of CatZAP(H₆) protein was carried out using cobalt column chelation chromatography, fractions eluted using 100 mM imidazole and kinase activity determined by ³²P transfer.

20 High throughput protein kinase screening assay

The interaction of the active protein kinase moiety with compounds of a combinatorial peptide library can be determined.

A rapid and very sensitive assay was developed for

25 measuring the amount of peptide substrate phosphorylation

- 68 -

produced by CatZAP(H₆). The peptide library was synthesised with a positively charged tetra-lysine tag. After peptide incubation with the protein kinase and ATP, containing trace amounts of radiolabelled [³³P-γ]-ATP, the reaction mixture is passed through a negatively charged phosphocellulose membrane using a 96 well plate vacuum manifold system (Millipore). Positively charged peptide is bound by the membrane, whereas unincorporated [³³P-γ]-ATP is washed through. Scintillant is then applied to the membrane and the amount of phosphorylated peptide calculated from the level of radioactivity on the membrane, measured using a well plate scintillation counter. This type of assay can be readily applied to other protein kinase systems.

The result of this screening assay is the identification of one or more protein kinase substrate motifs, which appear to have the common features of a negatively charged N-terminus and a conserved Pro at the C-terminus. For other protein tyrosine kinases, the existing libraries may provide some information, although it is envisaged that additional libraries will require to be built. For Ser/Thr kinases, the technology may be adapted by the use of a central Ser or Thr residue as the phosphoacceptor moiety.

In addition, technology is being developed within the chemistry department which will allow for the generation of cyclic peptide libraries. Incorporation of a central phosphoacceptor residue in these libraries will provide a source of constrained molecules for use in kinase assays.

- 69 -

Abbreviations

Abbreviations used herein are as follows:

Abbreviations for amino acids and nomenclature of peptide structures follow the recommendations given in: IUPAC-IUB Commission on Biochemical Nomenclature, (*J. Biol. Chem.*, 247, 997, 1971). All chiral amino acids are of the L configuration unless otherwise stated. Other abbreviations used are :

-Abu , b-amino butyric acid, : Abz, 2-amino benzoyl : ACH,
 1-amino-1-carboxy-cyclohexane : ACP, 1-amino-1-carboxy-
 cyclopropane : Bip, Biphenylalanine : n-Bu, n-
 butoxycarbonyl : Bz, Benzoyl : Bz(2-carboxy), 2-
 carboxybenzoyl : Bu^oGly, tert-Butylglycyl : BOP,
 benzotriazolyl-oxy-tris-(dimethylamino)-phosphonium
 hexafluorophosphate: Cha, cyclohexylalanine : Chex, 1-
 carboxycyclohexyl : eAHA, gamma aminohexanoyl : HBTU, O-
 benzotriazolyl-N,N,N',N'-tetramethyluronium
 hexafluorophosphate: HOBT, 1-hydroxybenzotriazole : Hyp,
 trans-4-hydroxyprolinyl : hLeu, homoleucyl : 2Nal, 2-
 naphthylalanine : NMM, N-methylmorpholine : Piv, pivoyl :
 3pyr, 3-pyridylalanine : Tic, 2-carboxytetrahydroquinolyl
 : Tyr(NO₂), 3-nitrotyrosine.

DMF, dimethylformamide; Fmoc, fluorenylmethoxycarbonyl;
 HPLC, high performance liquid chromatography; Pfp,
 pentafluorophenyl, tBoc, tert-butoxycarbonyl; tBu, tert-
 butyl; TFA, trifluoroacetic acid; Pmc, pentamethyl

- 70 -

chroman, Phf, pentamethylbenzofuran, TBTU, 2-(1H-Benzotriazole-1-yl)-1,1,1,3,3-tetramethyluronium tetrafluoroborate; Trt, Trityl.

p.Aba, 4-aminobenzoyl; Aib, Aminoisobutyric acid; Bip,
5 Biphenylalanine; nBu, n-Butyl; Bz, Benzoyl; Cmpi,
Carboxymethylpiperazine; Deg, Diethylglycine; DIPEA, N,N-Diisopropyl-ethylamine; HATU, O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HOAT, 1-hydroxy-7-azabenzotriazole; Naph, Naphthylalanine; 3.Pyr,
10 3-pyridiylalanine; Tyr(NO₂), 3-nitro-tyrosine.

- 71 -

References

1. I. Schlechter and A. Berger, Biochem. Biophys. Res. Commun., 1967, 27, 157-162)
2. A. Carmel et al., FEBS Lett., 1973, 30, 11.
- 5 3. M. M. Meldal and I. Svendsen, J. Chem. Soc. Perkin Trans.1, 1995, 1591-1596,
4. M. Meldal and K. Breddam, Anal. Biochem., 1991, 195, 141-147,
5. T. Forster, Ann. Phys., 1948, 6, 55.
- 10 6. A. Yaron, A. Carmel, and E. Katchalski-Katzir, Anal. Biochem. 1979, 95, 228 and references therein.
7. S.A. Latt et al., Anal. Biochem., 1972, 50, 56.
8. A. Persson et al., Anal. Biochem., 1977, 83, 2,96.
9. I. Yu Filppova et al., Bioorg. Khim., 1986, 12, 1172.
- 15 10. J. Pohl et al., Anal. Biochem., 1987, 165, 96.
11. S.J. Pollack et al., J. Am. Chem. Soc., 1989, 111, 5961.
12. E. K. Bratovanova and D.D. Petkov, Analytical Biochem., 1987, 162, 213.
- 20 13. J. Singh et al., J. Med. Chem., 1995, 38, 217-219 and references therein.
14. M. Green et al. in 'Innovation and Perspectives in Solid Phase Synthesis' (R. Epton Ed.) Mayflower Worldwide Ltd., Birmingham, UK. 1994, 239-244.
- 25 15. J. R. Petithory et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 11510-11514

- 72 -

16. J. Berman et al., J. Biol. Chem., 1992, 267, 1434-1437.
17. H. Drevin, A. -T. Martin, J. Carlsson, S. Oscarsson, T. Lovgren, I. Hemmila and M. Kwiatkowski,
5 WO89/10975, (5-5-1988)
18. A. J. Garman and N. G. Phillips, WO 94/28166 (27-5-1993)
19. G.T. Wang and E.D. Matayoshi, E.P. 428000 (3-11-1989)
- 10 20. G. A. Krafft, G. T. Wang and E.D. Matayoshi, EP 428000, (3-11-1989).
21. G. R. Marshall and M. V. Toth, USP 5,164,300, (11-12-1990).
22. G. R. Marshall and M. V. Toth, USP 5,011,910, (28-
15 12-1989).
23. K. T. Chapman, N. A. Thornberry, M. Maccoss, J. R. Weidner, R. A. Mumford, W. K. Hagmann, EP 528487A (16-8-1991)
24. R. P. Haugland, WO 93/04077, (23-8-1991)
- 20 25. R. M. Valerio, A. M. Bray N. J. Maeji, Int. J. Peptide Protein Res., 1994, 44, 158-165
26. M. Bastos, N. J. Maeji and R. H. Abeles, Proc. natl. Acad. Sci., 1995, 92, 6738-6742.
27. 'Solid Phase Peptide Synthesis', E. Atherton and R.
25 C. Sheppard, IRL Press 1989.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: PEPTIDE THERAPEUTICS LIMITED
- (B) STREET: 321 CAMBRIDGE SCIENCE PARK
- (C) CITY: CAMBRIDGE
- (D) STATE: CAMBRIDGE
- (E) COUNTRY: ENGLAND
- (F) POSTAL CODE (ZIP): CB4 4WG
- (G) TELEPHONE: 01223 423333
- (H) TELEFAX: 01223 423111

(ii) TITLE OF INVENTION: Auto-deconvoluting Combinatorial Libraries

(iii) NUMBER OF SEQUENCES: 52

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "X at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "X at position 4 is Nle"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "X at position 6 is Tyr(NO2)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Xaa Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Xaa Val Ala Lys Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Xaa Val Ala Gln Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION:1
      (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION:6
      (D) OTHER INFORMATION:/note= "Xaa at position 6 is
          Tyr(NO2)"
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Xaa Val Ala Thr Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION:1
      (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION:4
      (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"
```

(ix) FEATURE:

76

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Xaa Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is Cha"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Xaa Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:1
(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Xaa Val Ala His Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

(i). SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:1
(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:4
(D) OTHER INFORMATION:/note= "Xaa at position 4 is 3pyr"

(ix) FEATURE:

- ```
(A) NAME/KEY: Modified-site
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "Xaa at position 6 is
 Tyr(NO2) "
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Xaa Val Ala Xaa Ser Xaa Asp  
1 5

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids  
(B) TYPE: amino acid



78

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Xaa Val Lys Xaa Ser Xaa Asp  
1                      5

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:3
- (D) OTHER INFORMATION:/note= "Xaa at position 3 is  
Met(O) "

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

79

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is Tyr(NO2) "

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Xaa Val Xaa Xaa Ser Xaa Asp  
1 5

## (2) INFORMATION FOR SEQ ID NO: 11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is Tyr(NO2) "

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Xaa Gln Ala Xaa Ser Xaa Asp  
1 5

## (2) INFORMATION FOR SEQ ID NO: 12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:1  
 (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"
- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:4  
 (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"
- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:6  
 (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
 Tyr(NO2) "
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
- Xaa Lys Ala Xaa Ser Xaa Asp  
 1 5
- (2) INFORMATION FOR SEQ ID NO: 13:
- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 7 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:1  
 (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"
- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:2  
 (D) OTHER INFORMATION:/note= "Xaa at position 2 is  
 Met(O) "
- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:4  
 (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"
- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:6  
 (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
 Tyr(NO2) "

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Xaa Xaa Ala Xaa Ser Xaa Asp  
1 5

## (2) INFORMATION FOR SEQ ID NO: 14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is 3pyr"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
Tyr(NO2) "

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Xaa Xaa Ala Xaa Ser Xaa Asp  
1 5

## (2) INFORMATION FOR SEQ ID NO: 15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

## (ix) FEATURE:

82

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is 2Nal"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
Tyr(NO2) "

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Xaa Xaa Ala Xaa Ser Xaa Asp  
1 . 5

## (2) INFORMATION FOR SEQ ID NO: 16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
Tyr(NO2) "

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Xaa Leu Ala Xaa Ser Xaa Asp  
1 5

## (2) INFORMATION FOR SEQ ID NO: 17:

83

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 7 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:1  
 (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:2  
 (D) OTHER INFORMATION:/note= "Xaa at position 2 is Cha"

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:4  
 (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:6  
 (D) OTHER INFORMATION:/note= "Xaa at position 6 is  
 Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Xaa Xaa Ala Xaa Ser Xaa Asp  
 1 5

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 7 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:1  
 (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION:2

(D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:4

(D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:6

(D) OTHER INFORMATION:/note= "Xaa at position 6 is  
Tyr(NO2)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Xaa Xaa Ala Xaa Ser Xaa Asp  
1 5

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:1

(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:2

(D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:4

(D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:6

(D) OTHER INFORMATION:/note= "Xaa at position 6 is  
Tyr(NO2)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Xaa Xaa Ala Xaa Tyr Xaa Asp

1

5

(2) INFORMATION FOR SEQ ID NO: 20:

- ```
(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 7 amino acids
    (B) TYPE: amino acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
    (A) NAME/KEY: Modified-site
    (B) LOCATION:1
    (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:
    (A) NAME/KEY: Modified-site
    (B) LOCATION:2
    (D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:
    (A) NAME/KEY: Modified-site
    (B) LOCATION:4
    (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:
    (A) NAME/KEY: Modified-site
    (B) LOCATION:6
    (D) OTHER INFORMATION:/note= "Xaa at position 6 is
        Tyr(NO2)"
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Xaa Xaa Ala Xaa Leu Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION:1
 - (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "xaa at position 4 is hLeu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Xaa Xaa Ala Xaa Lys Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Xaa Xaa Ala Xaa Asp Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:1
(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:2
(D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:4
(D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:5
(D) OTHER INFORMATION:/note= "Xaa at position 5 is Abu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Xaa Xaa Ala Xaa Xaa Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

88

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/product= "X"
/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Xaa at position 5 is Cha"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Xaa Xaa Ala Xaa Xaa Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2

(D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 4

(D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION:/note= "Xaa at position 5 is Met(O) "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 6

(D) OTHER INFORMATION: /note= "Xaa at position 6 is Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Xaa Xaa Ala Xaa Xaa Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2

(D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 4

(D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 6

(D) OTHER INFORMATION:/note= "Xaa at position 6 is

Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Xaa Xaa Ala Xaa Thr Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION:1
(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION:2
(D) OTHER INFORMATION:/note= "Xaa at position 2 is BIP"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION:4
(D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION:5
(D) OTHER INFORMATION:/note= "Xaa at position 5 is 3pyr"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

Xaa Xaa Ala Xaa Xaa Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids

91

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Xaa at position 5 is BuGly"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Xaa at position 6 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Xaa Xaa Ala Xaa Xaa Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:2
 (D) OTHER INFORMATION:/note= "Xaa at position2 is Bip"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:4
 (D) OTHER INFORMATION:/note= "Xaa at position 4 is hLeu"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:5
 (D) OTHER INFORMATION:/note= "Xaa at position 5 is Hyp"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:6
 (D) OTHER INFORMATION:/note= "Xaa at position 6 is
 Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

Xaa Xaa Ala Xaa Xaa Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 30:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 8 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:1
 (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:2
 (D) OTHER INFORMATION:/note= "Xaa at position 2 is 1
 Naph"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:5
 (D) OTHER INFORMATION:/note= "Xaa at position 5 is Nle"
- (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:7
- (D) OTHER INFORMATION:/note= "Xaa at position 7 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

Xaa Xaa Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:2
- (D) OTHER INFORMATION:/note= "Xaa at position 2 is Bip"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Xaa at position 5 Is Nle"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:7
- (D) OTHER INFORMATION:/note= "Xaa at position 7 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Xaa Xaa Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION:/note= "Xaa at position 1 is Abz"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION:/note= "Xaa at position 5 is Nle"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 7

(D) OTHER INFORMATION: /note= "Xaa at position 7 is
Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Xaa Lys Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEO ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: /note= "Xaa at position 1 is Abz"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION:/note= "Xaa at position 5 is Nle"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 7

(D) OTHER INFORMATION:/note= "Xaa at position 7 is Tyr(NO2) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Xaa Glu Val Ala Xaa Ser Xaa Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in position 1 is
n-benzoyl"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa ain position 4 is
l-norleucine bromomethyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in position 1 is
N-benzoyl"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa ainm position 4 is

L-norleucine 2,6-bis(trifluoromethyl)benzoyloxomethyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Xaa Val Ala Xaa

1

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in position 4 is
L-norleucine 2,6-bimethylbenzyloxomethyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Xaa Val Ala Xaa

1

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in position is
L-norleucine 2-hydroxybenzoyloxomethyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

Xaa Val Ala Xaa

1

(2) INFORMATION FOR SEQ ID NO: 38:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:1
 (D) OTHER INFORMATION:/note= "Xaa in position 1 is
 N-benzoyl"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:4
 (D) OTHER INFORMATION:/note= "Xaa in position 4 is
 L-norleucine 2,6-dichlorobenzoyloxomethyl ket..."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:
- Xaa Val Ala Xaa
1
- (2) INFORMATION FOR SEQ ID NO: 39:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:1
 (D) OTHER INFORMATION:/note= "Xaa in position 1 is
 N-benzoyl"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:4
 (D) OTHER INFORMATION:/note= "Xaa in position 4 is
 L-norleucine benzoyloxomethyl ketone"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:
- Xaa Val Ala Xaa
1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 42:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:1
(D) OTHER INFORMATION:/note= "Xaa in position 1 is
N-benzoyl"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:4
(D) OTHER INFORMATION:/note= "Xaa in position 4 is
L-norleucine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:5
(D) OTHER INFORMATION:/note= "Xaa in position 5 is
N(benzyloxycarbonyl)-D-serinyl-(O-tert-butyl)oxymethyl
ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Xaa Val Ala Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 43:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION:4
(D) OTHER INFORMATION:/note= "Xaa in position 4 is
L-norleucine"

100

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Xaa in position 5 is
N(-benzyloxycarbonyl)-D-serineoxy methyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Xaa Val Ala Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in position 1 is
N-benzoyl"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in position 4 is
L-norleucine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Xaa in position 5 is
2-furanoxy methyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Xaa Val Ala Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

101

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:1

(D) OTHER INFORMATION:/note= "Xaa in position 1 is
N-benzoyl"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:4

(D) OTHER INFORMATION:/note= "Xaa in position 4 is
L-norleucine 2,6-dichlorophenylacetyloxy methyl ketone"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Xaa Val Ala Xaa

1

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:1

(D) OTHER INFORMATION:/note= "Xaa in the 1 position is
Ethyl-(s)-(e)-3-TERT BUTOXY CARBONYL"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:4

(D) OTHER INFORMATION:/note= "xAA IN THE 4 POSITION is
amino-6-methyl-hept-2-enoate"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Xaa Val Ala Xaa

1

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

102

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in the 1 position is
(S) - (E) -3- (tertbutoxycarbonyl) "

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in the 4 position is
amino-6-methyl-hept-2-enoic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in the 1 position is
1,1,1-trifluoroethyl- (S) - (E) -3- (tertbutoxycarbonyl) "

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in the 4 position is
amino-6-methyl-hept-2-enoate"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 49:

103

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in the 1 position is Ethyl-(S)-(E)-3-(N-benzoyl)"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in the 4 position is amino-6-methyl-hept-2-enoate"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in the 1 position is (S)-(E)-3(tertbutoxycarbonyl)"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in the 4 position is amino-1-phenylsulfonyl-5-methyl-1-hexene"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in the 1 position is
(S) - (E) -3-tertbutoxycarbonyl"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in the 4 position is
amino-1-methylsulfonyl-5-methyl-1-hexene"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

Xaa Val Ala Xaa
1

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:


- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/note= "Xaa in the 1 position is
Diehtyl(S) - (E) -3((tert-butoxycarbonyl))"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Xaa in the 4 position is
5-methylhexenylsulfonate"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

1. A complementary pair of compound libraries L1 and L2 containing compounds which interact with an active moiety, the libraries comprising two orthogonal sets of mixtures of compounds in solution providing two complementary combinatorial libraries (referred to as primary and secondary libraries) indexed in two dimensions for autodeconvolution, thereby allowing characterisation of an active motif in any group of compounds, wherein libraries L1 and L2 constitute a set containing compounds having four variable groups B, C, D, E of formula:



3. A method according to claim 2 wherein the format complies with general deconvolution formulae in which:

- 107 -

$$(i) \quad ns = \frac{Rp.Cp}{Rs.Cs} Np$$

$$(ii) \quad k = b.c.d.np.e$$

$$(iii) \quad k = x.N.np$$

$$5 \quad (iv) \quad N = Rp.Cp$$

$$(v) \quad K = X.Rp.Cp.np$$

$$(vi) \quad b.c.d.e = X.Rp.Cp$$

$$(vii) \quad Cp.e = X$$

$$(viii) \quad Rp.e = X, \text{ if } Rp=Cp$$

10 and wherein

np = number of primary plates
 ns = number of secondary plates
 Rp = number of primary rows
 Rs = number of secondary rows
 15 Cp = number of primary columns
 Cs = number of secondary columns
 K = number of combinations of compounds
 N = number of wells on a plate, and
 X = number of compounds per well.

20 4. A method according to claim 3 wherein

np = 4
 ns = 16
 Rp = 8
 Rs = 4
 25 Cp = 10
 Cs = 5

K = 6400
N = 80
X = 20

5. A method according to claim 2 wherein the active
5 moiety is selected from the group consisting of enzymes,
receptors and antibodies.

6. A method according to claim 5 wherein interaction of
the active moiety with the compounds of the library is
selected from the group consisting of the interaction of a
10 substrate or inhibitor with an enzyme, the interaction of
a ligand with a receptor, and the interaction of an
antigen or antigenic epitope with an antibody.

7. A method according to claim 5 wherein the active
moiety is selected from the group consisting of the
15 following enzyme classes:

1. Oxidoreductase
 - a) dehydrogenase
 - b) oxidase
 - c) peroxidase
 - 20 d) catalase
2. Hydrolase
 - f) peptidase (proteolytic enzyme)
3. Transferase
 - g) aminotransferase
 - h) kinase
 - 25 i) glucosyltransferase
4. Lyase
 - j) decarboxylase
 - k) dehydratease

5. Isomerase
1) racemase
m) mutase

6. Ligase
n) synthetase
o) carboxylase

5

8. A method according to claim 7 wherein the active moiety is a protease selected from the group consisting of the following:

- 10 . 1. Aspartyl proteases, such as renin, HIV, cathepsin D and cathepsin E.
2. Metalloproteases, such as ECE, gelatinase A and B, collagenases, stromolysins.
3. Cysteiny l proteases, such as apopain, ICI, DerPI, cathepsin B, cathepsin K.
- 15 4. Serine proteases, such as thrombin, factor VIIa, factor Xa, elastase, trypsin.
5. Threonyl proteases, such as proteasome S.

9. A method according to claim 2 wherein the active moiety is a kinase and the interaction is with a kinase substrate or inhibitor.

20

10. A method according to claim 2 wherein the active moiety is a receptor and the interaction is with a ligand.

11. A method according to claim 2 wherein the active moiety is an antibody and the interaction is with an antigen or antigenic epitope.

25

12. A method according to claim 2 wherein the mixture of compounds in all of the wells of primary library L1 contain all variations of a first two variable groups and each well contains a unique pair of the two other variable groups; and wherein the mixture of compounds in all of the wells of secondary library L2 contain all variations of the two other variable groups and each well contains a unique pair of the first two variable groups.

13. A method according to claim 12 wherein the primary library contains all variations of variable groups B and E, and unique pairs of variable groups C and D; and the secondary library contains all variations of variable groups C and D, and unique pairs of variable groups B and E.

14. A method according to claim 2 or 3 which comprises the steps of forming libraries according to claim 1, placing the libraries into the wells of well plates in a format according to claim 2 or 3, applying an active moiety to the wells, screening for an interaction of the active moiety with one or more compounds of a mixture in a well of primary library L1 and secondary library L2 and deducing from the respective L1 and L2 well positions a unique active compound formula.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 1/04, G01N 33/68		A1	(11) International Publication Number: WO 97/42216 (43) International Publication Date: 13 November 1997 (13.11.97)									
(21) International Application Number: PCT/GB97/01158 (22) International Filing Date: 24 April 1997 (24.04.97) (30) Priority Data: <table><tr><td>9608457.9</td><td>24 April 1996 (24.04.96)</td><td>GB</td></tr><tr><td>9616115.3</td><td>31 July 1996 (31.07.96)</td><td>GB</td></tr><tr><td>9624584.0</td><td>27 November 1996 (27.11.96)</td><td>GB</td></tr></table> (71) Applicant (for all designated States except US): PEPTIDE THERAPEUTICS LIMITED [GB/GB]; 321 Cambridge Science Park, Milton Road, Cambridge CB4 4WG (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): QUIBELL, Martin [GB/GB]; 23 Fennec Close, Cherry Hinton, Cambridge CB1 4GG (GB). JOHNSON, Tony [GB/GB]; 10 Brookside Grove, Littleport, Ely, Cambridgeshire CB6 1JN (GB). HART, Terance [GB/GB]; 12 Perry Court, Clerk Maxwell Road, Cambridge CB3 0RS (GB). (74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).			9608457.9	24 April 1996 (24.04.96)	GB	9616115.3	31 July 1996 (31.07.96)	GB	9624584.0	27 November 1996 (27.11.96)	GB	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
9608457.9	24 April 1996 (24.04.96)	GB										
9616115.3	31 July 1996 (31.07.96)	GB										
9624584.0	27 November 1996 (27.11.96)	GB										
(54) Title: AUTO-DECONVOLUTING COMBINATORIAL LIBRARIES												
(57) Abstract <p>The present invention relates to the field of apparatus and methods which provide the rapid generation of structure/activity relationships using auto-deconvoluting combinatorial libraries, which facilitate the invention of novel active compounds. The invention provides apparatus and methods which can be used for the rapid generation of structure/activity relationship (SAR) data, and, therefore, the characterisation of the active motif of any group of compounds. The invention provides libraries of compounds which interact with an active moiety, and apparatus and methods to identify such compounds. The active moieties may be (but are not limited to) enzymes, receptors, antibodies, etc. The interaction of the active moiety with the compounds of the library may be (but is not limited to) the interaction of a substrate or inhibitor with an enzyme, the interaction of a ligand with a receptor, the interaction of an antigen or antigenic epitope with an antibody, etc.</p>												

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

1/17

	1	2	3	4	5	6	7	8	9	10	11	12
A	A1	A2	A3	A4	A5	A6	A7	A8	A9	A10		
B	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10		
C	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10		
D	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10		
E	E1	E2	E3	E4	E5	E6	E7	E8	E9	E10		
F	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10		
G	G1	G2	G3	G4	G5	G6	G7	G8	G9	G10		
H	H1	H2	H3	H4	H5	H6	H7	H8	H9	H10		

Figure 1

2/17

First Example of Library Matrix where n=1

Component Distribution in Plate 1, Library 1 (n=1)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
D1	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D2	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D3	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D4	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D5	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D6	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D7	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D8	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂

Figure 2

3/17

Component Location in Plate 1, Library 2 (n=1).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E2	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂

Figure 3

4/17

Component Location in Plate 2, Library 2 (n=1).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄
E2	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄	D ₃₋₄

Figure 4

5/17

Component Location in Plate 3, Library 2 (n=1).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆
E2	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆	D ₅₋₆

Figure 5

6/17

Component Location in Plate 4, Library 2 (n=1).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₉	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₉	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E2	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈

Figure 6

7/17

Example Library where $n=4$ Component Distribution in Plate 1, Library 1 ($n=4$)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
D1	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D2	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D3	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D4	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D5	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D6	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D7	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂
D8	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂	B ₁₋₁₀ E ₁₋₂

Figure 7

8/17

Component Location in Plate 2, Library 1 (n=4)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
D1	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D2	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D3	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D4	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D5	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D6	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D7	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄
D8	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄	B ₁₋₁₀ E ₃₋₄

Figure 8

9/17

Component Location in Plate 3, Library 1 (n=4)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
D1	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D2	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D3	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D4	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D5	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D6	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D7	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆
D8	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆	B ₁₋₁₀ E ₅₋₆

Figure 9

10/17

Component Location in Plate 4, Library 1 (n=4).

	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
D1	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D2	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D3	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D4	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D5	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D6	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D7	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈
D8	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈	B ₁₋₁₀ E ₇₋₈

Figure 10

11/17

Component Location in Plate 1, Library 2 (n=4).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E2	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E3	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E4	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E5	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E6	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E7	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂
E8	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀	C ₁₋₁₀
	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂	D ₁₋₂

Figure 11.

12/17

Component Location in Plate 2, Library 2 (n=4).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E2	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E3	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E4	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E5	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E6	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E7	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄
E8	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄	C ₁₋₁₀ D ₃₋₄

Figure 12

13/17

Component Location in Plate 3, Library 2 (n=4).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E2	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E3	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E4	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E5	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E6	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E7	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆
E8	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆	C ₁₋₁₀ D ₅₋₆

Figure 13

14/17

Component Location in Plate 4, Library 2 (n=4).

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10
E1	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E2	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E3	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E4	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E5	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E6	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E7	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈
E8	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈	C ₁₋₁₀ D ₇₋₈

Figure 14.

15/17






Figure 15




5




6

Figure 16




4

A



m.w. 460.965

B



m.w. 434.927

Figure 17





Figure 18

179-28
FGN/37520

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

AUTO-DECONVOLUTING COMBINATORIAL LIBRARIES

the specification of which (check applicable box(es)):

- ☐ is attached hereto
☒ was filed on October 23, 1998 as U.S. Application Serial No. 09/171,671 (Atty Dkt. No. 179-28)
☒ was filed as PCT International application No. PCT/GB97/01158 on 24 April 1997
☐ and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
9608457.9	U.K.	24 April 1998
9616115.3	U.K.	31 July 1996
9624584.0	U.K.	27 November 1996

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
PCT/GB97/01158	24 April 1997	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; William J. Griffin, 31260; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090.

1. Inventor's Signature: M. Quibell Date: 22nd DEC 1998
 Inventor: Martin (first) Quibell (last) UK (citizenship)
 Residence: (city) Cambridge (state/country) England
 Post Office Address: 23 Fennec Close, Cherry Hinton, Cambridge, England
 (Zip Code) CB1 4GG

2. Inventor's Signature: J. Johnson Date: 22nd DEC 1998
 Inventor: Tony (first) Johnson (last) UK (citizenship)
 Residence: (city) Cambridge (state/country) England
 Post Office Address: 10 Brookside Grove, Littleport, Ely, Cambridge, England
 (Zip Code) CB6 1JN

3. Inventor's Signature: L. Hart Date: 26/5/99
 Inventor: Terance (first) Hart (last) UK (citizenship)
 Residence: (city) Cambridge (state/country) England
 Post Office Address: 12 Perry Court, Clerk Maxwell Road, Cambridge, England
 (Zip Code) CB3 0RS

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.